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General Abstract 
The developmental remodelling of motivational systems that underlie drug 
dependence and addiction may account for the greater frequency and severity of drug 
abuse in adolescence compared to adulthood. Recent advances in animal models have 
begun to identify the morphological and the molecular factors that are being remodelled, 
but little is known about the culmination of these factors in altered sensitivity to 
psycho stimulant drugs, like amphetamine, in adolescence. Amphetamine induces potent 
locomotor activating effects in rodents through increased dopamine release in the 
mesocorticolimbic dopamine system, which makes locomotor activity a useful 
behavioural marker of age differences in amphetamine sensitivity. The aim of the thesis 
was to investigate the neural basis for age differences in amphetamine sensitivity with a 
focus on the nucleus accumbens and the medial prefrontal cortex, which initiate and 
regulate amphetamine-induced locomotor activity, respectively. 
In study 1, I found pre- and post- pubertal adolescent rats to be less active (i.e., 
hypoactive) than adults to a first injection of 0.5, but not of 1.5, mg/kg of intraperitonealy 
(i.p.) administered amphetamine. Although initially hypoactive, only adolescent rats 
exhibited an increase in activity to a second injection of amphetamine given 24 h later, 
indicating that adolescents may be more sensitive to the rapid changes in amphetamine-
induced plasticity than adults. Given that the locomotor activating effects of 
amphetamine are initiated in the nucleus accumbens, age differences in response to direct 
injections of amphetamine into this brain region were investigated in study 2. In contrast 
to i.p. injections, adolescents were more active than adults when amphetamine was given 
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directly into the nucleus accumbens, indicating that hypo activity may be attributed to the 
development of regulatory regions outside of the accumbens. 
The medial prefrontal cortex (mPFC) is a key regulator of the locomotor 
activating effects of amphetamine that undergoes extensive remodelling in adolescence. 
In study 3, I found that an i.p. injection of 1.5, and not of 0.5, mg/kg of amphetamine 
resulted in a high expression of c-fos, a marker of neural activation, in the pre limbic 
mPFC only in pre-pubertal adolescent rats. This finding suggests that the ability of 
adolescent rats to overcome hypo activity at the 1.5 mg/kg dose may involve greater 
activation of the prelimbic mPFC compared to adulthood. In support of this hypothesis, I 
found that pharmacological inhibition of prelimbic D 1 dopamine receptors disrupted the 
locomotor activating effects of the 1.5 mg/kg dose of amphetamine to a greater extent in 
adolescent than in adult rats. In addition, the stimulation of prelimbic D 1 dopamine 
receptors potentiated locomotor activity at the 0.5 mg/kg dose of amphetamine only in 
adolescent rats, indicating that the prelimbic D1 dopamine receptors are involved in 
overcoming locomotor hypoactivity during adolescence. 
Given my finding that the locomotor activating effects of amphetamine rely on 
slightly different mechanisms in adolescence than in adulthood, study 4 was designed to 
determine whether the lasting consequences of drug use would also differ with age. A 
short period of pre-treatment with 0.5 mg/kg of amphetamine in adolescence, but not in 
adulthood, resulted in heightened sensitivity to an injection of amphetamine given 30 
days after the start of the procedure, when adolescent rats had reached adulthood. The 
finding of an age-specific increase in amphetamine sensitivity is consistent with evidence 
for increased risk for addiction when drug use is initiated in adolescence compared to 
111 
adulthood in people (Merline et aI., 2002), and with the hypothesis that adolescence is a 
sensitive period of development. 
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CHAPTER 1: GENERAL INTRODUCTION 
Drug use and adolescence 
Adolescence is a period of development during which individuals are driven to 
explore novel stimuli, as evidenced by high levels of sensation-seeking and risk taking 
during this period of development (reviewed in Spear, 2000 Steinberg, 2004). The drive 
to explore often extends to drugs of abuse to such an extent that experimentation with 
drugs in adolescence may be considered normative (Spear, 2000). However, a lot of 
evidence suggests that the consequences of drug use in adolescence are more severe than 
are the consequences of drug use in adulthood. For example, adolescents progress from 
drug use to dependence more rapidly than adults (Clark, Kirisci, & Tarter, 1998), and 
adults who initiated drug use in adolescence suffer from more serious dependence 
problems than those who initiated drug use later in life (e.g., Clark et aI., 1998; Merline, 
O'Malley, Schulenberg, Bachman, & Johnston, 2004; Windle, Spear, Fuligni, Angold, & 
Brown, 2008). Psychostimulants, including cocaine and methamphetamine, represent the 
greatest abuse problem in the United States (Vetulani, 2001) and a growing concern in 
Canada. According to Health Canada, cocaine and amphetamine use has been on the rise 
since 1994, in large part because of increasing drug use in adolescence (Adlaf, Begin, & 
Sawka, 2005). Amphetamine in particular is abused world-wide because of its cheaper 
cost and longer lasting effects compared to cocaine (Klee, 1992; Murray, 1998; Selden, 
1991). 
Animal models of drug use and addiction 
Animal models are essential for developing an understanding of drug-responsive 
neural circuits and for mapping cause and effect relationships between environmental 
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manipulations, development, and propensity for drug abuse. For findings from animal 
models to be translated to people, animal models must meet the criteria for face, 
construct, and predictive validity (Sanchis-Segura & Spanagel, 2006; Schramm-Sapyta, 
2004; Spear, 2000). In the rodent model of drug abuse, face validity is evaluated based on 
similarities in drug-taking behaviour between people and rodents, whereas predictive 
validity is evaluated by the ability of drug responses in rodents to predict responses in 
people. Both criteria are met by the fact that when given the opportunity, rodents self-
administer and avoid the same drugs that people do, such that drug use in rodents can 
successfully predict the abuse potential of drugs in people (Koob, 2000; Sanchis-Segura 
& Spanagel, 2006). Finally, construct validity is assessed based on overlapping drug-
responsive neural circuitry, which is remarkably similar in people and in rodents 
(Schramm-Sapyta, 2004). 
The main goal of research in animal models is to identify the risk factors that 
increase the probability of drug abuse and addiction (Sanchis-Segura & Spanagel, 2006). I 
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Drug abuse is defined as the improper use of legal or illegal drugs for the purpose of j 
altering mood or consciousness (Cuddy, 2003), whereas addiction is a disorder ofthe 
central nervous system, characterized by compulsive drug use, craving and drug seeking 
in spite of negative consequences and at the expense of personal relationships (Cuddy, 
2003; Schramm-Sapyta, 2004; Vetulani, 2001). Addiction develops over a long period of 
drug intake, which in rats may require at least 3 months of drug exposure (Deroche-
Gamonet, Belin, & Piazza, 2004). For this reason, most animal work has focused on 
modeling specific behavioural components that lead to addiction, rather than the 
culmination of these components in addiction (Sanchis-Segura & Spanagel, 2006). 
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Specifically, individual differences in the rewarding and stimulating effects of drugs in 
the early stages of drug use, as well as individual differences in adaptations to repeated 
drug use, are associated with different levels of addiction risk (Haertzen, 1986; Haertzen, 
Kocher, & Miyasato, 1986; Robinson & Berridge, 1993; Robinson & Berridge, 2000). 
For this reason, many studies focus on individual, environmental, and developmental 
factors that are involved in altering the reinforcing and stimulating effects of drugs. 
An additional goal of research with animal models is to use pharmacological tools 
to investigate the functions of different neurotransmitter systems and to map functions of 
specific neural regions and circuits. Different drugs of abuse elicit effects on behaviour 
by altering distinct aspects of neurochemical balance (Luscher & Ungless, 2006), which 
makes them useful for investigating neural responses to pharmacological stimulation or 
inhibition of various neurotransmitter systems. Drugs can also be used to identify drug-
responsive neural regions by injecting them directly into specific sites in the brain 
through surgically implanted cannulae. Comparisons of behavioural outcomes produced 
by these injections are then used to identify the relative contribution of different regions 
in production of a single behavioural outcome, or to identify distinct roles for different 
regions in distinct behavioural outcomes (Ikemoto & Wise, 2004). The latter approach 
has been particularly useful for identifying the neural substrates that are involved in drug 
addiction, based on evidence that all addictive drugs, irrespective of their primary 
mechanism of action, involve actions on common neural substrates, most notably the 
mesocorticolimbic dopamine system (discussed below) (Nestler, 2005). 
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Animal models of drug reward 
Drugs are positive reinforcers that elicit quantifiable approach behaviours in 
rodents (Koob, 2000; Robinson & Berridge, 2000; Shippenberg & Koob, 2002). Drug-
seeking can be defined as an increase in the rate of drug consumption with repeated 
administrations, or as the development of a preference for the drug. The most commonly 
used measures of reinforcing value of drugs in rodents include self-administration and 
conditioned place preference (CPP). In self-administration paradigms, animals are 
implanted with a drug-delivery device that they can learn to control by performing an 
instrumental action. Drug delivery can occur on a fixed schedule, whereby the drug is 
administered after a fixed number of instrumental actions (e.g., lever presses) have 
occurred, or on a progressive ratio schedule, whereby the number of instrumental actions 
required to obtain the drug increases progressively throughout the procedure. Both 
procedures provide information about the animal's desire (wanting) to consume the drug, 
and the latter allows for evaluation of the animal's motivation to work for the drug as the 
cost of obtaining the drug increases (Sanchis-Segura & Spanagel, 2006). 
Conditioned place preference (CPP) is a classical conditioning procedure that has 
been argued to measure a variety of reinforcing properties of drugs, including their 
hedonic value, drug-seeking behaviour, drug liking, and drug wanting (Bardo & Bevins, 
2000; Shippenberg & Koob, 2002). CPP involves the repeated pairing of a drug with a 
specific environmental cue and pairing of saline (i.e., vehicle) with another cue. The 
reinforcement value of the drug is measured by the difference in time spent on the drug-
paired cue relative to the saline-paired cue (Bardo & Bevins, 2000). Conversely, an 
animal is considered to have developed aversion to the drug when they spend more time 
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on the saline compared to the drug-paired cue. Validity of this tool is supported by 
evidence that rodents develop a preference for drugs that are reinforcing in people and an 
aversion for drugs that have known negative effects in people (Shippenberg & Koob, 
2002). 
Locomotor activating effects of psychostimulants 
In addition to producing reinforcing effects, psycho stimulants increase locomotor 
activity in rodents. Locomotor activating and reinforcing effects of psycho stimulants are 
closely associated, as demonstrated by their reliance on similar neural circuitry (e.g., 
Robinson & Berridge, 1993; Robinson & Berridge, 2000; Smith, Tindell, Aldridge, & 
Berridge, 2009; Wise & Bozarth, 1987). This relationship is thought to exist because 
reinforcing stimuli must elicit approach behaviours in order for organisms to interact with 
and obtain the reinforcing stimulus (Mogenson, Jones, & Yim, 1980). Essentially, 
locomotor activity may be considered as an easily measured component of translating 
motivation into action (Mogenson et aI., 1980), which has made this measure a widely 
used index of psycho stimulant actions in the central nervous system. 
Locomotor sensitization 
Repeated, intermittent administration of psycho stimulants results in locomotor 
sensitization, which is defined as the progressive augmentation of locomotor activity with 
successive drug treatments (e.g., Kuczenski, Segal, & Todd, 1997; Lett, 1989; Lorrain, 
Arnold, & Vezina, 2000; Robinson & Berridge, 2000; Shippenberg & Koob, 2002). 
Although sensitization is most commonly assessed with respect to locomotor activity, this 
phenomenon has also been reported for the reinforcing effects of drugs. For example, 
amphetamine pre-treated rats worked harder to self-administer amphet~mine compared to 
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saline pre-treated rats on a progressive-ratio schedule of reinforcement (Vezina, Lorrain, 
Arnold, Austin, & Suto, 2002). These data suggest that amphetamine pre-treatment 
increases the sensitivity to amphetamine's subsequent reinforcing effects and reduces the 
sensitivity to the increasing cost associated with the high number of lever presses 
required to obtain the drug (Vezina et a!., 2002). This increase in sensitivity to the 
locomotor activating and reinforcing effects of drugs is thought to reflect the neural 
processes involved in transition from drug abuse to addiction (Robinson & Berridge, 
1993; Robinson & Berridge, 2000), which has made locomotor sensitization a commonly 
used measure of addiction risk in rats. 
Drug-responsive neural circuitry 
All addictive drugs, including psycho stimulants like amphetamine, increase 
dopamine activity in the mesolimbic dopamine system, which is thought to be the basis 
oftheir addictive properties (Nestler, 2005; Pierce & Kumaresan, 2006). Amphetamine is 
a dopamine releaser and an uptake inhibitor that increases levels of the neurotransmitter 
dopamine in the synapse (Feldman, Meyer, & Quenzer, 1997). Although amphetamine 
can enter the cell through passive diffusion, the majority of its effects are produced 
through interactions with the dopamine transporter on the presynaptic cell. Under normal 
conditions, dopamine in the synapse is transported back into the cell by binding to its 
transporter, thereby reducing the amount of transmitter in the extracellular space. When 
amphetamine binds to the dopamine transporter, it causes it to reverse direction, thereby 
moving dopamine out of the synaptic terminal (Leshner & Koob, 1998; Seiden, Sabol, & 
Ricuarte, 1993). This process is referred to as reverse transport and it results in dopamine 
overflow throughout neural regions that contain the dopamine transporter, including the 
.1 
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nucleus accumbens (Sellings & Clarke, 2003; Vezina, 2004), prefrontal cortex (Shoblock, 
Maisonneuve, & Glick, 2004), and the ventral tegmental area (Adell & Artigas, 2004). 
This overflow has been implicated in reinforcing and locomotor activating effects of 
amphetamine (Lorrain, Riolo, Matuszewich, & Hull, 1999; Vezina, 2004). 
Dose and route of administration 
Effects of amphetamine on behaviour are dose-dependent. In most laboratory 
studies, systemic administrations of amphetamine are given intraperitonealy (i.p.) into the 
body cavity, although subcutaneous injections are also used. With these routes of 
administration, amphetamine doses ofless than 0.1 mglkg do not produce an observable 
effect on behaviour. Doses between 0.1 and 0.4 mglkg represent the EDso (an effective 
dose that produces a response in 50% of rats) range and generally induce an increase in 
locomotor activity. Doses between 0.4 to 1.0 mglkg reliably increase locomotor activity 
in adult rats and intensity oflocomotion is increased with high doses (1.0 to 3.0 mglkg). 
Doses greater than 3.0 mg/kg are considered to be very high, such that locomotor activity 
is suppressed and is replaced by stereotypy (Grilly & Loveland, 2001; Rebec, White, & 
Puotz, 1997). Stereotypy refers to a set of repetitive behaviours, such as head bobbing 
and sniffing, which normally occur at a single location in the apparatus, and may be more 
closely associated with psychosis and aversion than with reward (Adriani, Chiarotti, & 
Laviola, 1998; Robinson & Becker, 1986). 
The mesocorticolimbic dopamine system refers to a group of related structures 
that are innervated by dopaminergic projections from the ventral tegmental area. The 
ventral tegmental area contains dopamine cell bodies with axons terminating in the 
nucleus accumbens (Feldman et aI., 1997; Gold, Geyer, & Koob, 1989; Vezina, 2004), 
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the amygdala (Fallon, 1988), the hippocampus (Swanson, 1982) and the prefrontal cortex 
(Leshner & Koob, 1998). The effects of psycho stimulants are initiated through actions in 
these brain regions, which regulate the expression and the intensity of reinforcing and 
locomotor activating effects of psycho stimulants (Pierce & Kalivas, 1997). 
The nucleus accumbens is directly implicated in the reinforcing and locomotor 
activating effects of psychostimulants. Lesions of dopamine terminals in the nucleus 
accumbens block psycho stimulant-induced locomotor activity (Joyce & Koob, 1981; 
Sellings & Clarke, 2003), self-administration (Koob, 2000), and conditioned place 
preference (Sellings & Clarke, 2003). Conversely, amphetamine is readily self-
administered directly into the nucleus accumbens (Phillips, Robbins, & Everitt, 1994) and 
administration of amphetamine into the nucleus accumbens produces a robust locomotor 
response (e.g., Fletcher, Korth, Sabijan, & DeSousa, 1998). These effects of 
amphetamine are blocked by administration of dopamine receptor antagonists (Phillips et 
aI., 1994) and are mimicked by administration of dopamine receptor agonists (e.g., 
Meyer, Van Hartesveldt, & Potter, 1993) into the nucleus accumbens, indicating that 
locomotor activating and reinforcing effects of amphetamine occur through 
amphetamine-induced enhancement of dopamine release in this brain region. Given its 
role in the locomotor activating and reinforcing effects of psychostimulants, the nucleus 
accumbens is thought to provide a functional link between limbic and motor systems, 
which is required for translation of motivation into action (Mogenson et aI., 1980). 
Although the locomotor activating and reinforcing effects of amphetamine exhibit 
extensive overlap, there is evidence for specialization of different subregions of the 
nucleus accumbens for each behaviour (e.g., Budygin et aI., 2004; Phil~ips, Setzu, & 
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Hitchott, 2003). The dorsal portion of the nucleus accumbens is referred to as the core, 
and the ventral portion as the shell, which can be further divided into ventral and medial 
portions (Feldman et aI., 1997; Ikemoto, Qin, & Liu, 2005). Lesions of dopamine 
terminals in the nucleus accumbens core blocked the expression of psychostimulant-
induced locomotor activity, but not conditioned place preference, whereas lesions in the 
shell blocked conditioned place preference and not locomotor activity (Sellings & Clarke, 
2003). Similarly, rats learned to self-administer amphetamine into the medial shell of the 
nucleus accumbens, but not into the ventral shell or the core (Ikemoto et aI., 2005). Thus, 
while locomotion and reward do co-occur and are generally predictive of one another, 
they can be localized to different, though proximal, regions in the brain. Furthermore, the 
proximity of these brain areas and their concurrent activation in the absence of surgical 
intervention support the view that locomotion and reward are closely related systems that 
function together to reinforce and drive behaviour. 
Other components of the mesocorticolimbic dopamine system are not directly 
involved in the initiation of behavioural responses to psychostimulants, although they do 
mediate these responses. For example, administration of amphetamine directly into the 
prefrontal cortex or the ventral tegmental area did not affect locomotor activity, but 
injections of amphetamine into these regions altered the locomotor activating effects of 
acute or repeated injections of systemically administered amphetamine (Kalivas & 
Webber, 1988; Lacroix, Broersen, Feldon, & Weiner, 2000). Similarly, amygdala lesions 
enhanced locomotor activating effects of systemically administered amphetamine 
although lesions alone had no effect on basal activity (Woods & Ettenberg, 2004). Thus, 
although amphetamine-induced locomotor activity is initiated in the nu~leus accumbens, 
the magnitude of the locomotor response is modulated by other components of the 
mesocorticolimbic dopamine system. 
Dopamine receptors 
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Dopamine binds to cell-surface receptors that are coupled to transmembrane G 
proteins, which allow the dopamine-receptor complex to alter levels of second 
messengers inside the cell. Association of dopamine with its receptor leads to activation 
of adenylate cyclase inside the cell, which catalyzes the conversion of adenosine 
triphosphate (ATP) into the second messenger cyclic adenosine monophosphate (cAMP). 
Accumulation of cAMP leads to the activation of protein kinase A (PKA), which 
regulates the active state of downstream effectors through phosphorylation of serine and 
threonine residues. One of the best understood targets of this signaling cascade is the 
cAMP response element binding (CREB) protein, which is a constitutively expressed 
transcription factor that becomes active when phosphorylated at serine 133 by protein 
kinase A (Herdegen & Leah, 1998). Once phosphorylated, CREB goes on to regulate the 
expression of genes associated with synaptic plasticity (Barco, J ancic, & Kandel, 2008). 
Phosphorylated CREB (PCREB) has received much attention in studies of addiction 
because of the ability of psycho stimulants to induce CREB phosphorylation throughout 
the mesocorticolimbic dopamine system (McGinty, Shi, Schwendt, Saylor, & Toda, 
2008), which also makes pCREB a useful measure of psycho stimulant-induced activation 
of neural regions. 
There are five subtypes of dopamine receptors that can be classified on the basis 
of their effects on cAMP synthesis as belonging to either the Dl-like or the D2-like 
dopamine receptor family (Moreira et aI., 2010; Nichols, 2010). Dl-lik~ receptors are 
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comprised of the D1 and D5 receptor subtypes and D2-like receptors are comprised of the 
D2, D3, and D4 receptor subtypes. The major distinction between the two classes of 
dopamine receptors is their opposing effect on cAMP, whereby D1-like receptors 
increase, and D2-like receptors decrease, cAMP accumulation in the cell (Neve, 
Seamans, & Trantham-Davidson, 2004; Romanelli, Williams, & Neve, 2010). Different 
actions of these receptors on cAMP are attributed to coupling to different G proteins. 
Specifically, D1 receptors are coupled to excitatory G proteins (Gas\Gaolf) that stimulate 
adenylate cyclase, whereas D2 receptors activate inhibitory G proteins (Gai) that inhibit 
adenylate cyclase and thus prevent the conversion of ATP to cAMP (Moreira et aI., 
2010). Although the cAMP-PKA cascade is most strongly associated with dopamine 
signaling, dopamine receptors also have effects on other signaling pathways, including 
the phosphoinositide and the mitogen-activated protein kinase cascades (Jin, Cai, Wang, 
Smith, & Friedman, 1998; Romanelli et aI., 2010). Moreover, dopamine receptors can 
also regulate neurotransmission through phosphorylation of ion channels, as well as 
glutamate and GABA receptor subunits (reviewed in Romanelli et aI., 2010). 
Role of dopamine receptors in the locomotor activating and reinforcing effects of 
amphetamine 
Functional roles of dopamine receptors are classically assessed with 
administration of dopamine receptor agonists and antagonists systemically or directly into 
the brain. Agonists are drugs that mimic effects of endogenous ligands and antagonists 
are drugs that antagonize or block the effects of endogenous ligands at the receptor(s) of 
interest. Indirect dopamine receptor agonists such as amphetamine increase the amount of 
dopamine available in the synapse, which leads to non-specific activation of dopamine 
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receptors (Romanelli et aI., 2010). For this reason, amphetamine and other indirect 
dopamine receptor agonists can be used to investigate the overall sensitivity of the central 
nervous system or of specific brain sites to dopamine stimulation, but no conclusions can 
be made about the role of specific receptors. For this reason, direct dopamine receptor 
agonists and antagonists have been developed that bind selectively to specific dopamine 
receptor classes or subtypes. Currently, no drugs are available that can distinguish 
between D 1 and D5 receptor subtypes, although many drugs have been developed that 
selectively bind to Dl-like receptor families (Nichols, 2010). For example, SCH 23390 is 
the first highly selective Dl-like receptor antagonist (Bourne, 2001) and SKF 81298 is a 
highly effective Dl-like receptor agonist (Desai, Terry, & Katz, 2005). A number ofD2 
receptor agonists and antagonists also exist, and many of these are selective for specific 
receptor subtypes (Prante, Dorfler, & Gmeiner, 2010), although some widely used drugs, 
like raclopride, act as potent antagonists at multiple D2-like receptor subtypes (Kohler, 
Hall, Ogren, & Gawell, 1985). These drugs have been widely used to investigate the 
function of different dopamine receptors in the central nervous system. 
Dopamine D I and D2 receptors are critical for the locomotor activating and 
reinforcing effects of psycho stimulants. Administration ofDI or D2 receptor agonists 
directly into the nucleus accumbens increases locomotor activity and injection ofDI or 
D2 receptor antagonists inhibits locomotor activity (Dreher & Jackson, 1989; Meyer, 
1993; Meyer et aI., 1993) . There is a synergistic effect ofDI and D2 receptor agonists in 
the nucleus accumbens, such that co-administration of both agonists increased locomotor 
activity more than administration of either agonist alone (Dreher & Jackson, 1989). 
Moreover, injection ofDI agonists alone into the nucleus accumbens is more effective at 
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increasing locomotor activity than is an injection of D2 agonists alone (Dreher & 
Jackson, 1989). In addition, injections of either D 1 or D2 receptor agonists directly into 
the nucleus accumbens effectively induce conditioned place preference (White, Packard, 
& Hiroi, 1991) and injections of either Dl or D2 receptor antagonists abolished 
amphetamine conditioned place preference (Liao, 2008). 
There is also a role for D 1 and D2 dopamine receptors in the medial prefrontal 
cortex, as injections of a D 1 receptor antagonist (Hall, Powers, & Gulley, 2009) or a 
combined DIID2 receptor antagonist (Bast, Pezze, & Feldon, 2002) into this brain region 
blocked locomotor activating effects of systemically administered amphetamine. Further, 
injections of D 1 receptor agonists into the medial prefrontal cortex increased preference 
for a low dose of systemically administered cocaine, although Dl receptor injection alone 
did not produce a preference (Brenhouse, Sonntag, & Andersen, 2008). The latter 
findings are consistent with a role for dopamine receptors in the medial prefrontal cortex 
in regulating locomotor activating and reinforcing effects of psychostimulants. 
Distribution of dopamine receptors in the mesocorticolimbic dopmaine system. 
An important source of functional differences in different dopamine receptor subtypes 
comes from differences in their distribution in the central nervous system (Romanelli et 
aI., 2010). The highest density ofDI dopamine receptors is found in the nucleus 
accumbens, moderate density is found in the amygdala, and lowest density in the ventral 
tegmental area, the hippocampus and the medial prefrontal cortex (Dubois, Savasta, 
Curet, & Scatton, 1986; Savasta, Dubois, & Scatton, 1986; Wamsley, Gehlert, Filloux, & 
Dawson, 1989). High density of D2 dopamine receptors is also found in the nucleus 
accumbens.and moderate density is found in the hippocampus, although density ofD2 
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receptors is much lower compared to Dl receptors in the cerebral cortex (Wamsley et aI., 
1989). The high distribution of both DI and D2 dopamine receptors in the nucleus 
accumbens compared to other neural sites is consistent with the primary role for 
dopamine receptors in modulation of motivated behaviour in this region. 
Defining adolescence 
Adolescence is a unique stage of development during which individuals must 
make the transition from being highly dependent on parents in childhood to becoming 
independent individuals with relationships outside of the home (Wahlstrom, Collins, 
White, & Lucian, 2010). As part of negotiating the successful transition into adulthood, 
adolescents place a high value on peer relationships outside of the home, they exhibit 
increased exploration of novel stimuli, and engage in higher levels of risk-taking and 
impulsive decision making compared to adults (Ernst, Romeo, & Andersen, 2009; Spear, 
2000; Wahlstrom et aI., 2010). Although this behavioural profile is often associated with 
negative outcomes, it is also thought to facilitate the successful transition into adulthood 
by allowing for exploration of adult roles (Silbereisen & Reitzle, 1992; Wahlstrom et aI., 
2010). 
The drive to explore unfamiliar stimuli and to seek novel peer relationships is in 
part driven by an enhanced sensitivity to the rewarding, and reduced sensitivity to 
aversive, stimuli during adolescence (Ernst et aI., 2009; Spear, 2000; Wahlstrom et aI., 
2010), which can place adolescents at an increased risk for drug abuse and addiction. In 
people, approximately half of all psychostimulant use is initiated in adolescence (Kandel 
& Logan, 1984; Wu & Schlenger, 2003), when rapid brain development alters 
vulnerability to addictive substances (Chambers, Taylor, & Potenza, 2~03; . Schramm-
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Sapyta, 2004; Smith, 2003). Use of illicit drugs in adolescence is associated with greater 
severity of drug abuse problems in adulthood (Merline et aI., 2004) and adolescents and 
young adults exhibit more rapid transition from drug use to dependence compared to 
adults (Spear, 2000; Wu & Schlenger, 2003). Nonetheless, there is far less research on 
the effects of psycho stimulants in adolescence using animal models than in adulthood. 
Rodent models of adolescence exhibit remarkable parallels to adolescence in 
people. As in people, adolescent rodents exhibit heightened levels of novelty seeking 
(Adriani et aI., 1998; Smith, 2003; Stansfield & Kirstein, 2006; Stansfield, Philipot, & 
Kirstein, 2004), impulsivity (Laviola, Adriani, Terranova, & Gerra, 1999; Schramm-
Sapyta, Walker, Caster, Levin, & Kuhn, 2009; Spear, 2000), and peer affiliation (Spear, 
2000), as well as increased sensitivity to rewarding and decreased sensitivity to aversive 
stimuli (Badanich, Adler, & Kirstein, 2006; Brenhouse, Dumais, & Andersen, 2010; 
Brenhouse, Sonntag et aI., 2008; Ernst et aI., 2009; Infurna & Spear, 1979; Schramm-
Sapyta, Morris, & Kuhn, 2006; Spear, 2000; Wahlstrom et aI., 2010) compared to adults. 
These parallels between people and rodents demonstrate the usefulness of rodent models 
for investigation of age differences in risk for drug abuse and addiction. 
Age span of adolescence 
Adolescence lacks a clear onset and offset as a period of development in people 
and rodents alike (reviewed in McCormick & Mathews, 2007; Sisk & Foster, 2004). In 
people, the onset of adolescence is considered to begin at the onset of puberty, though 
many cognitive and social developments associated with adolescence continue thereafter 
(Sisk & Foster, 2004). Onset of adolescence is also defined by chronological age, usually 
marked by the beginning of teenage years in people (13 yrs of age) (Waylen & Wolke, 
2004) and has been argued to conclude anywhere from 5-8 years following the onset of 
puberty (Rosenfeld & Nicodemus, 2003). A typical definition of adolescence in the 
rodent model is that of Tirelli and colleagues (Tirelli, Laviola, & Adriani, 2003), which 
divides adolescence into early- (postnatal day (P) 21; P21 - P34), mid- (P34 - P45), and 
late- (P45 - P59) stages. Most rodent research using adolescents to date has focused on 
the early stage, often concluding around "puberty", which begins at approximately 40 
days of age in males and 35 days of age in females based on the markers of the day of 
preputial separation in males and the day of vaginal opening in females (reviewed in 
McCormick & Mathews, 2007). 
Animal models of drug use in adolescence 
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Adolescent rats differ in response to psychostimulant treatment from adults, with 
adolescents typically exhibiting a reduced locomotor response to initial (acute) 
amphetamine treatment (Adriani & Laviola, 2000; Bolanos, Glatt, & Jackson, 1998; 
Lanier & Isaacson, 1977; Mathews & McCormick, 2007). Age differences in response to 
amphetamine may at least in part depend on dose, with some studies finding that age 
differences in locomotor activity can be reduced with high doses of amphetamine (~ 2.5 
mglkg) and reversed with very high doses of amphetamine (> 5.0 mglkg) (Adriani & 
Laviola, 2000; Bolanos et aI., 1998). Studies with cocaine have produced mixed results, 
with some fmding reduced (Frantz, O'Dell, & Parsons, 2006; Schramm-Sapyta, Pratt, & 
Winder, 2004) and others finding enhanced (Badanich, Maldonado, & Kirstein, 2008) 
locomotor activity in adolescents compared to adults. Irrespective of the direction of the 
effect, most studies find that adolescents and adults ·differ in psycho stimulant-induced 
" 
locomotor activity, which suggests that underlying neural substrates are differentially 
sensitive to psycho stimulant treatment during adolescence. 
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Studies of adolescence often do not discriminate between pre- and post-pubertal 
adolescent rats, although there is evidence to suggest that the behavioural response to 
psychostimulants may change over stages of adolescence. For example, post-pubertal 
(P44), but not pre-pubertal (P27) adolescent rats exhibited higher conditioned place 
preference for 10.0 mg/kg cocaine compared to adults (Brenhouse, Sonntag et aI., 2008), 
whereas P35, and not P45, rats exhibited greater preference than adults for 5.0 mg/kg 
cocaine (Badanich et aI., 2006). Stage of adolescence may also. influence locomotor 
activating effects to psycho stimulants, with some evidence fmding that P34 rats did not 
respond to either 2.0 or 5.0 mg/kg doses of amphetamine, whereas P45 rats responded to 
both doses (Lanier & Isaacson, 1977). Differences between stages of adolescence were 
also found for cocaine-induced locomotor activity, with P35, and not in P45, exhibiting 
higher levels of activity rats compared to adults (Badanich et aI., 2006). Overall, these 
studies suggest that sensitivity to psychostimulants may change in a non-linear fashion 
over different stages of adolescence. 
Adolescent rats also develop locomotor sensitization to repeated psychostimulant 
treatment more readily than adults (Adriani et aI., 1998; Laviola et aI., 1999; Mathews & 
McCormick, 2007; Schramm-Sapyta et aI., 2004), indicating that the adolescent brain 
may be more readily shaped by psychostimulants. Indeed, treatment with 
psycho stimulants in adolescence can induce locomotor sensitization that persists into 
adulthood (Achat-Mendes, Anderson, & Itzhak, 2003; Adriani et aI.,2006; Brandon, 
Marinelli, Baker, & White, 2001; Burton, Nobrega, & Fletcher, 2010; Kolta, Scalzo, Ali, 
& Holson, 1990; Marin, Cruz, & Planeta, 2008; McPherson & Lawrence, 2005; Ujike, 
Tsuchida, Akiyama, Fujiwara, & Kuroda, 1995), although it is not clear to what extent 
these effects are specific to adolescence, as most studies do not include an adult-pre-
treated comparison group. 
Adolescent development of the mesocorticolimbic dopamine system 
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These behavioural differences in psychostimulant responses between adolescents 
and adults most likely reflect ongoing development of the mesocorticolimbic dopamine 
system. The triadic theory of the neurobiology of motivated behaviour in adolescence 
(Ernst & Fudge, 2009; Ernst, Pine, & Hardin, 2005; Ernst et aI., 2009) posits that age 
differences in behaviour are associated particularly with the development of, and 
connectivity between, three key regions: the nucleus accumbens, the amygdala, and the 
medial prefrontal cortex. These regions are of particular interest because they undergo 
extensive changes in adolescence, but also because their primary functions map on well 
to age differences in motivated behaviour during adolescence. According to the theory, 
the nucleus accumbens, the primary function of which is to mediate appetitive behaviour, 
is argued to be in a heightened state during adolescence, which biases adolescents to seek 
out rewarding stimuli. At the same time, the amygdala, the primary function of which is 
to mediate responses to aversive stimuli, is thought to be in a lowered functional state 
during adolescence, which makes adolescents less sensitive to negative stimuli. Finally, 
the medial prefrontal cortex, which weighs the inputs from these regions, is thought to be 
biased in favour of appetitive stimuli in adolescence. Thus, the increased engagement in 
risky behaviour, novelty seeking, drug use, and impulsive decision making during 
adolescence are thought to occur because of functional changes in thes.e key regions, 
although the relative contribution of each region in regulating behavioural responses in 
adolescence has not been directly investigated. 
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The structures outlined in the triadic theory are strongly interconnected. For 
example, the nucleus accumbens receives glutamatergic projections from the amygdala 
(Robinson & Beart, 1988) and from the medial prefrontal cortex (porrino & Lyons, 
2000), and the medial prefrontal cortex and the amygdala have dense reciprocal 
connections (Groenwegen, Wright, Beijer, & Voorn, 1999). Each ofthese regions and the 
connections between them are remodelled during adolescence. In the nucleus accumbens 
and the prefrontal cortex, D 1 and D2 dopamine receptors are overproduced throughout 
early adolescence, reach peak levels between P28 and P40 and are subsequently pruned 
to adult levels, although pruning is protracted in the mPFC compared to the NAc 
(Andersen, Thompson, Rutstein, Hostetter, & Teicher, 2000; Gelbard, Teicher, Faedda, & 
Baldessarini, 1989; Giorgi et aI., 1987; Tarazi & Baldessarini, 2000). In both regions, 
basal levels of cAMP are higher in adolescence (P40) than in adulthood and the ability of 
D 1 and D2 dopamine receptors to regulate cAMP levels is reduced in adolescence 
(Andersen et aI., 2000). In contrast, dopamine transporter density in the NAc reaches 
adult levels by P28, with no evidence of subsequent pruning (Galineau, Kodas, 
Guilloteau, Vilar, & Chalon, 2004). Dopaminergic projections from the ventral tegmental 
area to the medial prefrontal cortex continue to increase throughout adolescence. and into 
young adulthood (>P60) (Berger, Verney, Febvret, Vigny, & Helle, 1985; Kalsbeek, 
Voorn, Buijs, Pool, & Uylings, 1988) and basal levels of dopamine in the nucleus 
accumbens increase between early and late adolescence (Badanichet aI., 2006). In 
addition, dopaminergic regulation of electrophysiological properties of.medial prefrontal 
cortex neurons and of prefrontal inputs to the nucleus accumbens matures between 
adolescence and adulthood (Benoit-Marand & O'Donnell, 2008; Tseng & O'Donnell, 
2007). 
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Morphological changes are also found in the medial prefrontal cortex and the 
amygdala in adolescence. Specifically, the volume of the prefrontal white matter 
increases between P30 and P90 in both sexes, whereas neuron number decreases in 
females more extensively than in males during the same period (Markham, Morris, & 
Juraska, 2007). The number of neurons and glia in the amygdala decreases from P35 to 
P90 (Rubinow & Juraska, 2009) and glutamatergic projections from the amygdala to the 
mPFC continue to increase until P60 (Cunningham, Bhattacharya, & Benes, 2002, 2008). 
Although the develoment ofthese regions likely contributes to age differences in 
response to psycho stimulants, it is not clear how these developmental changes translate to 
age differences in behaviuor. Site-specific injections that are commonly used in adult rats 
have not been employed in the study of age differences in the sensitivity of individual 
components of the mesocorticolimbic dopamine system. 
Puberty 
Puberty is only one aspect of adolescence, as many developmental changes in the 
brain and behaviour occur independently of gonadal hormones, and behavioural and 
cognitive adaptations continue after puberty has passed (Pinyerd & Zipf, 2005; Spear, 
2000). Puberty refers to the attainment of sexual maturity and is marked by increased 
pulsatility of the gonadotropin-releasing hormone (GnRH) and hypothalamic-pituitary-
gonadal (HPG) axis activation (e;g., Payne, Kelch, Murono, & Kerlan, 1977; Wiemann, 
Clifton, & Steiner, 1989). GnRH is synthesized in the median eminen~e of the basal 
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hypothalamus and it signals the pituitary to release gonadotropins, including lutenizing 
hormone and follicle stimulating hormone, which direct the production of sperm, eggs, 
and steroid hormones from the testes and ovaries (reviewed in Sisk & Foster, 2004). 
Sixty days of age is generally thought to constitute adulthood, as physical and sexual 
maturity is achieved at this time (McCormick & Mathews, 2007; McCormick, Mathews, 
Thomas, & Waters, 2010). 
Changes in hormone levels associated with adolescent maturation may be 
important for regulating at least some aspects of age differences in drug responses. 
Gonadal hormones are involved in regulating activity of the drug responsive 
mesocorticolimbic circuitry (Kuhn et aI., 2010). Sex differences in drug responses 
emerge in adolescence, with females exhibiting higher levels of psycho stimulant-induced 
locomotor activity and greater sensitivity to the reinforcing effects of psychostimulants 
than males (Becker, Molenda, & Hummer, 2001; Kuhn, Walker, Kaplan, & Li, 2001; 
Parylak, Caster, Walker, & Kuhn, 2008). Moreover, sex hormones mediate rewarding 
effects of psycho stimulants (WaIf, Rhodes, Meade, Harney, & Frye, 2007), although 
estrogen appears to be more effective than testosterone at regulating drug responses 
(Becker et aI., 2001). The extent to which changes in gonadal hormones during puberty 
alter sensitivity to psychostimulants is less clear, but some evidence suggests that 
prepubertal gonadectomy alters the sensitivity to drug responses in adulthood (Forgie & 
Stewart, 1994a; Parylak et aI., 2008). 
Goal of the dissertation 
Studies of adolescence in rodents have only recently gained momentum and much 
remains unknown about the factors that alter sensitivity to psychostimu}ant responses in 
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adolescence. Much of the available research is focused on understanding age differences 
in adaptations to prolonged periods of psychostimulant treatment, with relatively few 
studies focusing on age differences in the initial response to amphetamine. Understanding 
age differences in response to acute amphetamine is crucial for understanding the basis 
for altered sensitivity to drug abuse in adolescence. For example, studies in adult rats 
have found that a single injection of a high dose of amphetamine is sufficient for 
inducing lasting locomotor sensitization (Vetulani, 2001), indicating that a single dose of 
amphetamine can have profound effects on subsequent drug responses. Given that 
adolescents appear to be more susceptible to developing locomotor sensitization than are 
adults (Adriani et aI., 1998; Laviola et aI., 1999; Mathews & McCormick, 2007; 
Schramm-Sapyta et at, 2004), an understanding of age differences in response to acute 
amphetamine treatment is of critical importance for understanding the basis for age 
differences in sensitivity to immediate and lasting effects of psychostimulants. 
Most studies of age differences in amphetamine responses that have been 
conducted thus far have used high doses (~2.0 mglkg) (Adriani et aI., 1998; Lanier & 
Isaacson, 1977; Niculescu, Ehrlich, & Unterwald, 2005) that are more closely associated 
with stereotypy than with locomotor activity (Grilly & Loveland, 2001). In contrast to 
locomotor activity, stereotypy is not dependent on the nucleus accumbens (Rebec et aI., 
1997), such that the use of high amphetamine doses may limit conclusions that can be 
drawn regarding functional differences in the primary region associated with reinforcing 
effects of psychostimulants. Further, most available studies are limited to a single stage 
of adolescence, with a large number of studies investigating pre-pubertal -adolescent rats, 
such that little is known about the extent to which neural and hormonal changes over 
different stages of adolescence contribute to age differences in drug responding. 
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The aim of this dissertation was to investigate age differences in locomotor 
activating effects of acute amphetamine in the dose range (0.5 and 1.5 mglkg) that is 
associated with a dose-dependent increase in locomotor activity, while having a minimal 
impact on stereotypy (Grilly & Loveland, 2001). The goal of study 1 (chapter 2) was to 
conduct comparisons of locomotor activating effects of amphetamine in pre- (P30) and 
post- (P45) pubertal adolescent and adult rats in the same experiment to determine 
whether sensitivity to amphetamine changes over different stages of adolescence. In 
study 1, we also included comparisons of male and female rats to determine whether age 
differences in drug-responses are influenced by sex, as most studies of adolescence have 
only included male rodents. In adult rats, females are more sensitive to the locomotor 
activating and reinforcing effects of psychostimulants than are males, in part because of 
the influence of ovarian hormones (Becker et aI., 2001). Thus, we investigated the 
potential role of gonadal horomones in regulation of age differences locomotor-activating 
effects of amphetamine in females that were ovariectomized before or after puberty, or in 
adulthood. Finally, we investigated developmental differences in tyrosine hydroxylase, a 
rate limiting enzyme in dopamine synthesis, as a marker of age differences in dopamine 
levels in the nucleus accumbens and the medial prefrontal cortex of rats. 
Given that the nucleus accumbens is directly involved in locomotor activating 
effects of amphetamine and that this region undergoes extensive remodelling in 
adolescence, study 2 (chapter 3)was designed to investigate age differences in the 
locomotor activating effects of amphetamine produced by injections d~rectly into the 
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nucleus accumbens. Having established that the sensitivity of the nucleus accumbens to 
the locomotor activating effects of amphetamine differs for adolescent and adult rats in 
study 2, study 3 (chapter 4) was designed to investigate the age differences in neural 
activation of the nucleus accumbens and the developing medial prefrontal cortex in 
response to the same doses of systemically administered amphetamine as in study 1 (0.5 
and 1.5 mg/kg). Specifically, in study 3, age differences in amphetamine-induced 
activation of the nucleus accumbens and the medial prefrontal cortex were investigated 
using CREB phosphorylation and the expression of the immediate early gene c-fos as 
markers of neuronal activation. Having established that amphetamine produces different 
patterns of neural activation in the medial prefrontal cortex of adolescent and adult rats, 
further experiments were conducted to investigate age differences in the functional 
contribution of D 1 dopamine receptors in the medial prefrontal cortex to locomotor 
activating effects of systemically administered amphetamine using injections of 
dopamine receptor agonists and antagonists directly into this region. 
Finally, to determine whether age differences observed in the acute effects oflow-
dose amphetamine treatment would result in different consequences for adolescent and 
adult rats, rats in study 4 (chapter 5) were pre-treated with a low dose of amphetamine in 
adolescence or in adulthood and were tested for locomotor sensitization 30 days after the 
initial injection, when all rats were adult. 
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CHAPTER 2: CHANGES IN HYPORESPONSIVENESS TO ACUTE 
AMPHETAMINE AND AGE DIFFERENCES IN TYROSINE HYDROXYLASE 
IMMUNOREACTIVITY IN THE BRAIN OVER ADOLESCENCE IN MALE AND 
FEMALE RATS 
Note: This section is based on the following article, with permission: Mathews, I.Z., 
Waters, P.G., & McCormick, C.M. (2009). Changes in hyporesponsiveness to acute 
amphetamine and age differences in tyrosine hydroxylase immunoreactivity in the brain 
over adolescence in male and female rats. Developmental Psychobiology, 51,417-428. 
Abstract 
We investigated locomotor hyposensitivity after amphetamine in early (postnatal day 30; 
P30) and late (P45) adolescent rats compared to adults (P70) in experiment 1. Locomotor 
activity was measured for 1 hr after the fIrst (acute) and second (24 hr later) injection of 
amphetamine (0.5 or 1.5 mg/kg). P30 and P45 rats were transiently hypoactive compared 
to adults, as indicated by reduced locomotor activity after acute amphetamine and 
enhanced activity after the second injection in adolescents only. In experiment 2, 
ovariectomy did not alter locomotor activity during habituation at any age compared to 
intact rats, and, as for intact adolescents, ovariectomized adolescents continued to be less 
active after amphetamine than adults, suggesting gonadal immaturity alone cannot 
account for age differences in experiment 1. However, ovariectomy attenuated the 
increase in activity after the second treatment. In experiment 3 involving untreated rats, 
tyrosine hydroxylase immunoreactivity was reduced in P30, P40, and P50 compared to 
P90 rats in the nucleus accumbens core and the medial prefrontal cortex. Thus, 
adolescents may have an increased threshold of behavioural activation that can be 
overcome with either a higher dose or with repeated amphetamine treatment, and may be 
related to changes in the dopamine system over development. 
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Introduction 
In humans, there are age differences in sensitivity to drug effects that may 
underlie the increased risk for drug abuse and addiction in adolescents than in adults 
(Weiss, Mirin, & Bartel, 1994; Wu & Schlenger, 2003b). Adolescent and adult rodents 
also differ in sensitivity to the behavioural effects of acute and repeated psychostimulant 
treatment (reviewed in Izenwasser & French, 2002; Laviola, Macri, Morley-Fletcher, & 
Adriani, 2003; Spear, 2000; Tirelli, Laviola, & Adriani, 2003). Some studies have found 
that adolescent rats have reduced locomotor activity after an acute injection of 
amphetamine (Adriani & Laviola, 2000; Bolanos et at, 1998; Mathews & McCormick, 
2007) or of cocaine (Frantz et at, 2006; Zombeck, Gupta, & Rhodes, 2009) compared to 
adults. Further, because adolescence is a transitional period covering the prepubertal and 
postpubertal time between weaning until sexual maturity (reviewed in McCormick & 
Mathews, 2007), sensitivity to amphetamine may also vary according to the age of 
adolescents under consideration. For example, male and female rats at postnatal Day 18 
(P18) and in adulthood (> P60) increased locomotor activity after an acute injection of 
amphetamine (2.0, 5.0, or 10.0 mg/kg) compared to saline controls (Lanier & Isaacson, 
1977). However, P45 rats required multiple treatments before an amphetamine induced 
increase in activity was observed and P34 rats did not respond at all (Lanier & Isaacson, 
1977). 
We previously reported that when adolescent and adult rats were compared 
directly using a lower range of doses of amphetamine (0.25, 0.5, or 1.0 mg/kg), P46 
females, but not males, were less active after acute amphetamine than adults (Mathews & 
McCormick, 2007), even though these females were in late adolescence and were 
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postpubertal (i.e., cycling since approximately P35) at the time of testing. Moreover, only 
the adolescent females exhibited a significant increase in locomotor activity after a 
second injection of amphetamine 48 hr later, such that the age difference observed after 
the acute injection was no longer evident (Mathews & McCormick, 2007). Thus, 
locomotor hypoactivity in adolescent females may be a transient phenomenon that may 
reflect increased plasticity compared to adults. In the latter study (Mathews & 
McCormick, 2007), locomotor activity was recorded in small boxes during the training 
phase of the amphetamine conditioned place preference procedure, and we have also 
found hypo activity to 1.0 mglkg of amphetamine in male and female rats on P45 under 
more standard tests oflocomotion with larger arenas (Mathews, Mills, & McCormick, 
2008). 
Thus, the first purpose of the present study was to determine whether acute 
hypo activity that is limited to the first injection of amphetamine would be evident in both 
sexes in a more traditional test oflocomotor activity [i.e., larger testing arena, longer test 
duration (60 instead of30 min)], and using a higher dose of amphetamine (1.5 mglkg) in 
addition to the 0.5 mglkg dose we used previously. In addition, given the evidence that 
sensitivity to amphetamine changes across different adolescent ages (Lanier & Isaacson, 
1977), we investigated the extent to which hypoactivity after amphetamine occurs in 
early adolescence in both males and females; thus, rats were tested either at P30, P45, or 
P70. Inclusion of different age groups in the same experiment also allowed for direct 
comparisons between rats at different adolescent ages to better characterize the trajectory 
of maturation of locomotor activity after amphetamine. 
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In a second experiment, we investigated the extent to which age differences in 
female rats were due to age differences in gonadal maturation, as sensitivity to 
psychostimulants is known to be regulated by estrogen in adult female rats (Festa & 
Quinones-Jenab, 2004; Forgie & Stewart, 1994a). This regulation likely develops in 
adolescence, as suggested by post-pubertal emergence of sex differences in sensitivity to 
cocaine (Kuhn et aI., 2001; Parylak et aI., 2008) and by altered cocaine (parylak et aI., 
2008) and amphetamine (Forgie & Stewart, I 994b ) sensitivity in adult female rats 
ovariectomized before puberty. Thus, to test whether differences in circulating ovarian 
hormones influence age differences in locomotor activity after amphetamine, we 
ovariectomized rats 6 days before amphetamine treatment either before puberty at P25, 
after puberty at P40, or in adulthood (P65). 
Finally, because age differences in stimulant sensitivity have been attributed to 
the development of the mesocorticolimbic dopamine system (Chambers et aI., 2003; 
Spear, 2000), and because adolescents and adults differ in baseline levels of extracellular 
dopamine in the nucleus accumbens (Badanich et aI., 2006), we examined whether age 
differences in tyrosine hydroxylase, the rate limiting enzyme in the production of 
catecholamines, also differed across adolescence and into adulthood in untreated rats. 
Different levels of tyrosine hydroxylase in the nucleus accumbens have been reported for 
different strains of rats (Beitner-Johnson, Guitart, & Nestler, 1991; Gulley, Everett, & 
Zahniser, 2007) and for rats that differ in activity in a novel environment and after 
amphetamine treatment [apomorphine susceptible/unsusceptible rats: van der Elst, 
Roubos, Ellenbroek, Veening, & Cools, 2005; high/low responders: Verheij, de Moulder, 
De Leonibus, van Loo, & Cools, 2008], indicating that this enzyme may also be a good 
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marker for age differences in amphetamine sensitivity. Thus, in experiment 3, we 
measured tyrosine hydroxylase immunoreactivity in brain regions associated with the 
increase in locomotor activity after amphetamine, including the core of the nucleus 
accumbens (Sellings & Clarke, 2003) and the striatum (Rebec et aI., 1997), as well as the 
medial prefrontal cortex, which has been implicated in regulation of activity in these 
brain regions (pierce & Kalivas, 1997). 
Methods 
Animals 
A total of 108 female and 64 male Long Evans rats from the Brock University 
colony were used in these experiments. The rats came from 20 different litters (20 
primiparous dams, 6 sires). For breeding, pair-housed females were provided with a male 
for 5 days, after which the male was removed from the cage, and approximately 10 days 
'i 
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later females were housed singly and provided with nesting material. Offspring were 
sexed and weighed on the first day oflife (PO), and the litters were not culled (mean litter 
size of 14, range 10 to 18; mean number of males = 6.6, mean number of females = 7.4). 
The rats were weaned at 21 days of age (P21) and housed in groups of four (two per cage 
after Day 50) same-sex rats in a temperature controlled colony room with a 12:12 h 
light:dark cycle (lights on 08:00 h) with unlimited access to food and water. No more 
than one male and one female rat from a litter were assigned to anyone experimental 
group. In experiment 1, male and female rats were tested at P30 (males: mean = 108.58 g, 
SD = 16.40, SEM = 4.73; females: mean = 98.67 g, SD = 16.88, SEM = 4.90), P45 
(males: mean = 235 g, SD = 25.99, SEM = 7.50; females: mean = 185.75 g, SD =23.81, 
SEM = 6.87) or P70 (males: mean = 455.5 g, SD = 37.89, SEM = 10.94; females: mean = 
271.25 g, SD = 21.83, SEM = 6.30). In experiment 2, female rats were ovariectomized 
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(OVX) via bilateral flank incisions while under anesthesia (ketamine andxylazine 
mixture). Ovaries were extracted through a small incision (~5 mm) just below the ribs 
and the space below each ovary was clamped and sutured to prevent bleeding. The ovary 
was removed and remaining tissue was returned to the abdomen and the opening was 
closed with wound clips. Rats were allowed 5 days for recovery before habituation to the 
test arenas at P30, P45, or P70. Use of animals was approved by the Brock University 
IACUC and followed Canadian Council on Animal Care and National Institutes of Health 
guidelines. 
Experiment 1 
The test apparatus consisted of white open-top melamine boxes [58 cm (length); 
58 cm (width); 58 cm (height)] with a melamine base. Four separate test arenas were 
used, and rats were always tested in the same arena. The arenas were cleaned after a test 
session with 50% ethanol. The arenas were illuminated indirectly by red light to reduce 
the suppressive effects of bright illumination on exploration. To habituate rats to the test 
conditions, on P30, P45, or P70, rats were injected with saline and then placed in the 
arenas for 30 min. In experiments 1 and 2, the first amphetamine (Sigma, UK) injection 
(0.5 or 1.5 mg/kg, i.p., dissolved in saline) was administered 24 hr after the habituation 
session (test Day 1; 1 h test session), followed by a second injection of the same dose 24 
hr later (test Day 2; 1 h test session). Six rats were included in each age, sex, and dose 
group. Immediately after saline injection on habituation day and amphetamine injection 
on test days, locomotor activity was recorded using a Sony colour video camera mounted 
above the center of the boxes and linked to a computer tracking system (Smart; San 
Diego Instruments, San Diego, CA) that measured the distance travele~ by the rat (cm). 
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We routinely fmd little change in locomotor activity after injection of saline over days of 
testing; the exception is when testing spans over a wide range of days in adolescence, 
there may be an increase in activity that is a reflection of development rather than simply 
an effect of repeated testing (Mathews & McCormick, 2007; Mathews et aI., 2008; 
McCormick, Robarts, Gleason, & Kelsey, 2004; McCormick, Robarts, Kopeikina, & 
Kelsey, 2005). In addition, we reliably find increased locomotor activity in rats at the 
ages under consideration in the present experiments after amphetamine with a 0.5 mglkg 
dose compared to saline treated rats, and more activity in amphetamine- than in saline-
treated rats across test days (Mathews & McCormick, 2007). Therefore, to minimize the 
number of animals used, saline control groups were not included, and instead we relied 
on locomotion during habituation as a within-individual control. 
Experiment 2 
In experiment 2, 16 rats were OVX before puberty (P25), 15 after puberty (P40) 
and 15 in adulthood (P65). Rats were allowed 5 days to recover and were then tested as in 
experiment 1. A recovery period of 5 days was chosen so that rats could be OVX before 
and after puberty and still be tested for locomotor activity at the same ages as rats in 
experiment 1. 
Experiment 3: Immunohistochemistry 
Tyrosine hydroxylase immunoreactivity was measured in 26 female and 28 male 
rats at P30, P40, P50 and P90. These ages were chosen to represent early, mid, and late 
stages of adolescence, and adulthood, respectively. Rats were deeply anesthetized and 
transcardially perfused with physiological saline and 4% paraformaldehyde in 0.1 M 
phosphate buffer (PH 7.4). Brains were placed in a 30% sucrose and p~aformaldehyde · 
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solution until they sank. Coronal sections (40 ~m thick) were collected throughout the 
medial prefrontal cortex [cingulate cortex area 1 and 2 (Cgl and Cg2)], nucleus 
accumbens core, and the caudate nucleus using a cryostat (ThermoShandon) and stored in 
cryoprotectant at 80°C until the immunohistochemistry procedure could be performed. 
Every sixth section was collected for immunohistochemistry resulting in a total of four 
sections within the coordinates from approximately bregma 1.20 mm and 2.18 mm 
according to Paxinos and Watson (Paxinos & Watson, 2005). These coordinates were 
selected based on evidence that amphetamine increases activity most strongly after direct 
injection into the caudal-central region ofthe nucleus accumbens core (Essman, 
McGonigle, & Lucki, 1993). 
Free floating sections were washed stringently in O.IM PBS with 0.3% Triton X 
(PBSx, pH 7.1), then in 0.3% hydrogen peroxide, and then again in PBSx. Next, the 
tissues were incubated for 90 min in 10% normal horse serum (NHS) (Sigma) and then 
for 24 hr at 4°C in 1 % NHS and tyrosine hydroxylase monoclonal primary antibody 
diluted at 1: 10,000 (Sigma). After incubation, the sections were washed three times in 
PBSx before incubation for 75 min in biotinylated anti-mouse immunoglobulin secondary 
antibody (Vector Laboratories) diluted at 1:500 (Vector Laboratories). The sections were 
again washed in PBSx and placed for 1 hr in Avidin-Biotin Complex (Vector 
Laboratories). After another three washes in PBSx, tissues were placed in 
diaminobenzidine solution according to the instructions on the substrate kit (DAB SK-
4100, Vector Laboratories) for 5 min. Immunostained sections were mounted onto slides, 
dried, and coverslipped with Permount. Sections were photographed at 400X 
magnification with a Nikon Eclipse brightfield microscope (see Figure. 2. 1 for regions in 
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which pictures were taken). TH-immunoreactivity (ir) was quantified using integrated 
optical density 3 SD above the background signal. Measures for each structure were 
averaged across hemispheres and sections, and animals for which there were fewer than 
four measures for a structure were excluded, resulting in final sample sizes of 6 ± 2 
measures per animal for each brain region and for each sex and age group (n = 8 - 12 per 
group). 
Figure 2.1. Regions used for the measurement of tyrosine hydroxylase immunoreactivity 
from the atlas of Paxinos and Watson (2005) as indicated by the black squares in the 
nucleus accumbens core, the caudate nucleus, and the medial prefrontal cortex (eg1 and 
Cg2). 
Statistics 
Statistical analyses consisted of factorial and mixed factor analyses of variance. 
Sex was included as a between group factor in experiments 1 and 3 and Age was included 
as a factor in all experiments. Analyses in experiment 1 and 2 included the within-group 
factor of Days (1 st and the 2nd amphetamine treatment day). Analyses were conducted for 
each dose separately. Main effects are not reported when they are obviated by 
interactions among effects. Similarly, two-way interactions are not reported when they 
are obviated by three-way interactions. Where appropriate, follow-up ~alyses were 
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conducted using F-tests for simple effects, paired t-tests and Fisher's protected least 
squares difference tests. 
Results 
Experiment 1 
Habituation. There was an interaction of Sex and Age for distance traveled during 
habituation (F(2,66) = 4.62, P = 0.01). P30 females traveled less than P45 and P70 
females (both p < 0.0001), and P45 and P70 females did not differ. P30 and P45 males 
traveled less than P70 males (p = 0.01 and 0.03, respectively), and P30 and P45 males did 
not differ. Females traveled longer distances than males at P45 (p = 0.002), but females 
and males did not differ significantly at P30 or P70 (see Figure 2.2 a). 
Locomotor Activity after Amphetamine. For the 0.5 mg! kg dose, there was an 
interaction of Sex and Age (F(2,30) = 3.97, P = 0.03) for locomotor activity over days of 
amphetamine treatment, whereby females traveled greater distances than males at P45 (p 
= 0.005) and P70 (p = 0.002), but not at P30. There also was an interaction of Age and 
Day (F(2,30) = 4.00, P = 0.03), whereby the increase in distance traveled from Day 1 to 
Day 2 was significant at P30 only (p = 0.003); on Day 1 (F(2,33) = 18.54, p < 0.0001), 
P30 rats traveled less than P45 (p = 0.02) and P70 (p < 0.0001) rats and P45 rats traveled 
less than P70 rats (p < 0.001); and on Day 2 (F(2,33) = 11.31, P < 0.0001), activity for 
P30 and P45 rats did not differ, and both traveled less than P70 rats (both p < 0.0001) 
(see Figure 2.2 b). For the 1.5 mg/kg dose, there was an interaction of Age and Day only 
(F(2,30) = 4.69, p = 0.017). Post hoc paired t-tests for sexes combined indicated that the 
increase in distance traveled from Day 1 to Day 2 was significant at P30 and P45 (both p 
< 0.0001) and not at P70. However, the age groups did not differ on either day (see 
Figure 2.2 c). 
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To examine the extent to which the differences in locomotor activity after 
amphetamine were simply a reflection of age differences in locomotor activity, Sex X 
Age X Day ANOVAwere conducted on the percent increase in locomotor activity on Day 
1 and Day 2 from activity during habituation (as a means of controlling for age 
differences and sex differences in general locomotor activity) for each dose separately. 
Sex was no longer a significant factor at any age, however the interaction of Age X Day 
remained significant for both doses (0.5 mg/ kg: F(2,30) = 5.57, P = 0.009, and 1.5 
mglkg: F(2,30) = 6.38, P = 0.005) (see Figure 2.2 d). For the 0.5 mg/kg dose, the 
difference in percent increase from habituation in distance traveled on Day 1 to Day 2 
was significant at P30 only (p = 0.004); on Day 1 (F(2,33) = 11.19, P < 0.0001), P30 and 
P45 rats traveled less than P70 rats (p < 0.0001 and p = 0.002); and on Day 2 (F(2,33) = 
7.27, P = 0.002), only the difference in activity between P45 and P70 rats was significant 
(p = 0.001). For the 1.5 mglkg dose, the difference in percent increase from habituation in 
distance traveled on Day 1 to on Day 2 was significant only for P30 and at P45 rats (both 
p < 0.0001), and there were no significant age differences on either day. 
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Figure 2.2. Mean (±SEM) distance traveled in males and females and the sexes combined 
(shaded regions) in three different postnatal (P) age groups (a) on habituation day 
(interaction of Sex X Age); after injections of either (b) 0.5 mg/kg amphetamine 
(interaction of Sex X Age and Age X Day) or (c) 1.5 mg/kg amphetamine (interaction of 
Age X Day); (d) with distance traveled after amphetamine each day graphed as percent 
increase from habituation day (interaction of Age X Day was significant for both doses). 
Matched numbers indicate significant age differences for a test day; # a significant sex 
difference (females> males) for an age group; *a significant within-age difference over 
the two amphetamine days. 
Experiment 2 
Habituation in Ovariectomized (OVX)Females. The main effect of Age was 
significant for locomotor activity during habituation (F(2,43) = 21.33, P < 0.0001): P30 
rats traveled less than did P45 (p = 0.001) and P70 (p < 0.0001) rats, and P45 rats 
traveled less than did P70 rats (p = 0.007) (see Figure 2.3 a). 
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Locomotor Activity after Amphetamine in Ovariectomized (OVX) Females. An 
Age X Day ANOV A for distance traveled after 0.5 mglkg of amphetamine obtained a 
main effect of Age (F(2,22) = 58.95, P < 0.0001): P30 rats traveled less than did P45 (p = 
0.001) and P70 (p < 0.0001) rats, and P45 rats traveled less than did P70 rats (p < 0.0001) 
(see Figure 2.3 b). The ANOVA for distance traveled after 1.5 mglkg of amphetamine 
also obtained an effect of Age (F(2,18) = 6.61, P = 0.007), such that P30 rats traveled less 
than P70 rats (p < 0.0001), and the distance traveled increased from Day 1 to Day 2 
(F(I,18) = 9.30, P = 0.007) (see Figure 2.3 c). 
To examine the extent to which the differences in locomotor activity after 
amphetamine were simply a reflection of age differences in locomotor activity, Age X 
Day ANOV A were conducted on the percent increase in locomotor activity on Day I and 
Day 2 from activity during habituation (see Figure 2.3 d). For the 0.5 mglkg dose, the 
interaction of Age X Day was significant (F(2,21) = 5.84, P = 0.009), whereby the 
percent increase in distance traveled from habituation to test was lower on both Day I 
and Day 2 in P30 (p = 0.006, P = 0.001) and P45 (p = 0.003 and 0.047) compared to P70, 
and P70 had a higher percent increase on Day 2 compared to Day 1 (p = 0.01). For the 
1.5 mg/kg dose, the effect of Day was significant (F(2, 18) = 10.68, P = 0.004), with 
greater percent increase in activity from baseline on Day 2 than on Da~ 1. 
Additional post hoc analyses were conducted to compare the OVX rats in 
experiment 2 to the intact females in experiment 1. 
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P30 rats. Intact and OVX rats did not differ in distance traveled during 
habituation (t(26) = 0.25, p = 0.81). The Surgery X Day ANOVA for the 0.5 mg/kg dose 
of amphetamine revealed a significant interaction (F(1,12) = 15.88, p = 0.002). Activity 
increased from Day 1 to Day 2 in intact, but not in OVX females (see earlier analyses), 
such that OVX females were less active than intact rats on Day 2 (p = 0.012), but not on 
Day 1. The Surgery X Day interaction was also significant (F(1,12) = 5.74, P = 0.03) for 
the 1.5 mg/kg dose, but follow up analyses indicated that activity increased from Day I to 
Day 2 for intact and for OVX females (both p < 0.05). The effect of Surgery was not 
significant on Day 1 or on Day 2. 
P45 rats. Intact and OVX rats did not differ in distance traveled during 
habituation (t(25) = 0.92, p = 0.37). The Surgery X Day ANOV A for the 0.5 mg/kg dose 
found a main effect of Surgery only (F(1,12) = 10.85, p = 0.006), such that OVX females 
were less active than intact females. At the 1.5 mg/kg dose, only the effect of Day was 
significant (F(1,II) = 11.32, p= 0.006), such that activity increased from Day I to Day 2 
in OVX (p = 0.02) and in intact rats. 
P70 rats. Intact and OVX rats did not differ in distance traveled during 
habituation (t(24) = 1.79, p = 0.09). The Surgery X Day ANOV A did not reveal any main 
effects or interaction at either dose. 
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Figure 2.3. Mean (±SEM) distance traveled in ovariectomizedfemales in three different 
postnatal (P) age groups (a) on habituation day; after injections of either (b) 0.5 mglkg 
amphetamine or (c) 1.5 mglkg amphetamine; (d) with distance traveled after 
amphetamine each day graphed as percent increase from habituation day (significant 
interaction of Age X Day for 0.5 mglkg, and significant main effect of Day for 1.5 mglkg). 
Matched numbers indicate significant differences between age groups for a test day; *a 
significant within-age difference over the two amphetamine days. 
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Experiment 3 
Separate Age X Sex ANDV A was conducted for each of the four brain regions. 
The main effect of Sex and the interaction of Age and Sex was not significant for any 
region, whereas the main effect of Age was significant in the caudate (F(3,44) = 9.13, P < 
0.001), the nucleus accumbens core (F(3,37) = 4.17, P = 0.012), Cgl (F(3,42) = 3.69, p = 
0.019), and Cg2 (F(3,45) = 4.27, P = 0.01). Post-hoc analyses indicated that in the 
caudate, P40 and P50 rats had reduced immunoreactivity compared to P30 (p = 0.002 for 
both) and P90 (p = 0.002 for both) rats, whereas P30 and P90 rats did not differ. In the 
nucleus accumbens core, P30 (p = 0.009), P40 (p = 0.004) and P50 (p = 0.002) rats had 
reduced immunoreactivity compared to P90 rats. In Cgl, immunoreactivity was reduced 
in P30 (p = 0.02) and P50 (p = 0.003) compared to P90 rats and in Cg2, P30 (p = 0.003), 
P40 (p = 0.004) and P50 (p = 0.04) rats had reduced immunoreactivity compared to P90 
rats (see Figure 2.4). 
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Figure 2.4. Mean (±SEM) tyrosine hydroxylase immunoreactivity (arbitrary units) infour 
different brain regions, (a) caudate nucleus, (b) nucleus accumbens core, (c) medial 
prefrontal cortex Cg1, and (d) medial prefrontal cortex Cg2, for separate postnatal (P) 
age groups. Matched numbers indicate significant differences between age groups. P30: 
n = 8, P40: n = 12; P50: n = 10; P90:n = 11. 
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Discussion 
The main findings of the experiments above are that early and late adolescent 
males and females were hyporesponsive after acute amphetamine treatment compared to 
adults, and adolescents significantly increased activity to a second dose of amphetamine 
whereas adults did not. The initial hyporesponsiveness to amphetamine in adolescence 
does not appear to be due to gonadal immaturity based on the results in ovariectomized 
rats, but may be related in part to reduced catecholamine function, as indicated by lower 
tyrosine hydroxylase expression in adolescence than in adulthood in untreated rats. The 
specific findings are discussed below. 
Locomotor activity after acute amphetamine treatment 
The results from experiment 1 indicated that rats in early and in late adolescence 
are hypoactive after acute treatment with 0.5 or 1.5 mg/kg of amphetamine compared to 
adults. The initial hyporesponsiveness was not due to reduced locomotor capacity in 
adolescents, because, first, there were no age differences in locomotor activity to the 
second administration of the higher dose of amphetamine, and second, because the 
pattern of age differences in locomotor activity after the first dose of amphetamine did 
not parallel age differences during habituation. However, when locomotor activity was 
calculated as the percent change from habituation (to control for age differences in 
baseline activity), the difference between adolescents and adults remained only for the 
lower dose. Other studies investigating locomotor activity (Bolanos et aI., 1998) and the 
acquisition of self administration (Shahbazi, Moffett, Williams, & Frantz, 2008) have 
also reported that age differences in rats are greater for low than for high doses of 
amphetamine. There also is evidence that the direction of age differen~es may reverse at 
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higher doses. Adriani and Laviola (Adriani & Laviola, 2000) found that male mice in 
mid-adolescence were less active than adults after 2.0 mg/kg and more active than adults 
after 10.0 mg/kg of amphetamine. 
Another study found greater locomotor activating effects of acute amphetamine 
treatment only in adults with doses of2.0 and 5.0 mg/kg and suppressed locomotor 
activity in adult, but not in adolescent rats with a 10 mg/kg dose (Lanier & Isaacson, 
1977). Thus, there appear to be differences in the dose-response curve for amphetamine 
for adolescents and adults, with a decreased sensitivity manifested in adolescence to 
lower doses of amphetamine. However, there is a lack of consistency across studies as to.. 
the doses of amphetamine to which adolescents are hypoactive (Bolanos et aI., 1998; 
Lanier & Isaacson, 1977; Mathews & McCormick, 2007), which may be due to testing 
conditions. A number of studies have shown that age differences in behavioral responses 
to psycho stimulants depend on environmental and testing factors, including the size and 
shape of the testing arena, familiarity with the testing arena, test duration, and 
experimenter handling (amphetamine: Adriani & Laviola, 2000; amphetamine and 
cocaine: Bignami, 1996; cocaine: Frantz et aI., 2006; cocaine: Schramm-Sapyta et aI., 
2004). 
Change in activity to second administration of amphetamine 
As predicted, we found that adolescent, but not adult rats, exhibited a significant 
increase in activity from the first to the second injection of amphetamine. For the 0.5 
mg/kg dose, P30 rats increased locomotor activity after the second amphetamine 
treatment and P45 rats remained hypoactive, whereas both P30 and P45 rats increased 
activity after the second injection of 1.5 mg/kg of amphetamine. The f~ct that locomotor 
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activity increased after only one additional treatment with amphetamine in adolescent, 
but not in adult rats, has important implications, as it suggests locomotor hypoactivity 
after acute amphetamine in adolescence is accompanied by heightened plasticity to 
repeated treatment. The age difference in the increase in activity after a second dose of 
amphetamine remained when age differences in baseline activity were controlled. Thus, 
the extent to which adolescents are less sensitive (activity after acute amphetamine) or 
more sensitive (increase in activity after repeated amphetamine) depends on the measure. 
Similarly, Shahbazi et aI. (Shahbazi et aI., 2008) also showed that adolescent rats were 
less sensitive than adults on some measures of self-administration and more sensitive on 
others (for example, adolescents had increased drug intake and faster acquisition of self-
administration than adults). 
Hypoactivity after an acute injection of amphetamine that is not evident after a 
second injection suggests adolescents may have a higher threshold of activation than 
adults, but this threshold can be more easily shifted with repeated drug treatment or with 
a higher dose in adolescents than in adults. The neural basis ofthis behavioral profile is 
not known. Amphetamine increases locomotor activity by increasing dopamine release in 
the nucleus accumbens (Sharp, Zetterstrom, Ljungberg, & Ungerstedt, 1987; Vezina, 
2004) and a single amphetamine treatment has been shown to induce different patterns of 
c-fos activation in this region in adolescent than in adult rats (Andersen, Leblanc, & Lyss, 
2001). The decreased expression of tyrosine hydroxylase in adolescents than in adults 
found here suggests there may be reduced catecholamine pools available for release by 
amphetamine in adolescents than in adults. Consistent with the latter evidence, Laviola 
and colleagues (Laviola, Pascucci, & Pieretti, 2001) found that adoles,?ent rats had lower 
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striatal dopamine release after acute amphetamine treatment compared to adults, but 
dopamine release was greater in adolescent than in adult rats that were repeatedly treated 
with amphetamine. Further, long term potentiation is enhanced in the nucleus accumbens 
during adolescence (Schramm, Egli, & Winder, 2002). Thus, enhanced drug-related 
change in locomotor behaviour is likely a reflection of greater plasticity in the 
mesolimbic circuitry in adolescence. 
Locomotor activating effects of amphetamine: sex differences and the effect of ovarian 
hormones 
Sex differences during habituation and in amphetamine induced locomotor 
activity were observed at P45 and P70 but not at P30 in the present study, such that 
females were more active than males in late adolescence and in adulthood (when females 
are post-pubertal, with estrous cycles beginning at approximately P35). Such a sex 
difference is well established in adult rats, and it has been attributed in large part to the 
potentiating effects of ovarian hormones in females (Becker et aI., 2001), whereas only 
minimal inhibitory effects of testosterone have been reported for males (Becker et aI., 
2001). Studies with cocaine have also found that sex differences emerge after puberty 
(Kuhn et aI., 2001; Parylak et aI., 2008), and prepubertal ovariectomy has been shown to 
decrease the behavioral effects of cocaine (Kuhn et aI., 2001) and amphetamine (Forgie 
& Stewart, 1994a) in adulthood. However, the effects of ovariectomy on drug responses 
in these studies were only examined in adulthood, so it is not clear whether lower 
circulating levels of ovarian hormones in adolescence contributed to age differences after 
amphetamine. 
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In experiment 2, there were no differences during habituation and few differences 
after amphetamine between intact and ovariectomized females at any age, suggesting the 
effects of ovariectomy are not attributable to the surgical procedure. The overall pattern 
of age differences in locomotor activity after amphetamine also did not change after 
ovariectomy, such that early and late adolescent females were still hypoactive compared 
to adults at both doses. As with intact rats, hypoactivity was no longer evident at the 1.5 
mg/kg dose when age differences in locomotor activity during habituation were taken 
into consideration. However, ovariectomy did attenuate the overall locomotor activity 
and the increase in activity to the second injection of amphetamine compared to intact 
rats. This increase was entirely abolished in early adolescent females at the 0.5 mg/kg 
dose and attenuated in early and in late adolescent females at the 1.5 mg/kg dose. Thus, 
age differences in locomotor activity after amphetamine do not appear to be influenced 
by age differences in circulating ovarian hormones, though ovarian hormones may 
nonetheless contribute to plasticity after repeated amphetamine treatment in adolescence, 
even before puberty. 
Gonadal hormones make important contributions to brain development and 
maturation over adolescence (Ahmed et aI., 2008; Sisk & Foster, 2004). However, their 
contribution to development of the mesocorticolimbic dopamine system over adolescence 
may be minimal. For example, prepubertal gonadectomy had no effect on the transient 
increase in striatal dopamine receptor overexpression that occurs in adolescence and did 
not alter the pattern of sex differences in dopamine receptors (Andersen, Thompson, 
Krenzel, & Teicher, 2002). 
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Tyrosine Hydroxylase 
Tyrosine hydroxylase immunoreactivity (TH-ir) was measured in untreated rats 
across adolescence (P30, P40, and P50) and in adulthood (P90) to determine whether 
catecholamine synthesis in regions associated with locomotor activating effects of 
amphetamine also changes in adolescence. Amphetamine enhances locomotor activity by 
increasing dopamine release in the nucleus accumbens core (Sellings & Clarke, 2003; 
Sharp et aI., 1987; Vezina, 2004) and to a lesser extent in the caudate (e.g., Rebec et aI., 
1997), and activity of these regions is regulated in part by dopamine in the medial 
prefrontal cortex (Pierce & Kalivas, 1997).We found that in general, TH-ir in all of these 
regions was lower in adolescence than in adulthood. 
TH-ir in the nucleus accumbens core was significantly lower in early, mid, and 
late stages of adolescence than in adulthood, but it is not clear how this may relate to 
extracellular levels of dopamine in this region. Frantz et aI. (2006) found no age 
differences in baseline dopamine between adolescent and adult rats using microdialysis, 
whereas Badanich et aI. (2006) found that P35 rats had lower and P45 rats had higher 
baseline dopamine levels in the nucleus accumbens compared to adults. However, group 
differences in baseline TH levels have been implicated in differential sensitivity to 
amphetamine, such that rats that are less sensitive to novelty also exhibit reduced 
locomotor activity after amphetamine treatment (e.g., Verheij & Cools, 2008). Reduced 
TH-ir (Verheij & Cools, 2008) and intracellular dopamine (Verheij et aI., 2008) in this 
region has been found in rats selected for reduced sensitivity to novelty and 
amphetamine. Thus, reduced dopamine in the nucleus accumbens core may have a role in 
hypoactivity after acute amphetamine treatment in adolescence. 
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In the caudate, TH-ir was reduced at P40 and P50, but no difference was found 
between P30 rats and adults. This is of note, given that greater changes in dopamine 
receptor density during adolescence have been reported for the caudate than for the 
nucleus accumbens (Andersen & Teicher, 2000; Teicher, Andersen, & Hostetter, 1995). 
Moreover, dopamine receptor density in this region was found to peak: at P28 to levels 
higher than for other stages of adolescence and for adulthood (Tarazi & Baldessarini, 
2000). Potential implications of age differences in TH-ir in this region are less clear than 
differences in the nucleus accumbens, as locomotor activating effects of amphetamine are 
more strongly associated with dopamine release in the nucleus accumbens, whereas 
stereotypy induced by higher doses of amphetamine is more strongly associated with 
activity in the caudate (Kelly, Seviour, & Iversen, 1975; Rebec et aI., 1997). However, 
decreased TH-ir observed at 40 and 50 days of age is consistent with evidence that 
adolescent rats (P43) have reduced basal and amphetamine-induced dopamine release in 
the dorsal striatum compared to adults (Laviola et aI., 2001). 
TH-ir was also reduced in both regions of the medial prefrontal cortex (mPFC) in 
adolescence compared to adulthood. These results are consistent with the suggestion that 
dopamine synthesis in the mPFC in adolescence may be reduced to compensate for 
increasing dopamine inputs to this region in adolescence (reviewed in Spear, 2000). An 
adolescent decline in TH-ir in the mPFC may be involved in altered sensitivity to 
amphetamine in adolescence, as dopamine release in this region is inversely related to 
dopamine release in the nucleus accumbens (pierce & Kalivas, 1997). Because TH-ir in 
the present study represents basal expression, it is not clear how dopamine release in 
either region would be influenced by amphetamine treatment. Howeve~, a recent study 
showed that activation of dopamine D2 receptors had opposite effects on synaptic 
responses of accumbal medium spiny neurons after PFC stimulation in slices from 
adolescent and adult rats (Benoit-Marand & O'Donnell, 2008), suggesting that age-
specific changes in dopamine synthesis may be involved in hyporesponsiveness to 
amphetamine. 
Conclusions 
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Data from the present set of experiments support previous findings that 
adolescence is a period of altered sensitivity to psycho stimulants. We demonstrated that 
adolescent rats were less active than adults after acute amphetamine and that this age 
difference was attenuated with a higher dose or with repeated amphetamine treatment. 
Thus, adolescents appear to have a higher threshold for behavioral activation after 
amphetamine than adults, which is consistent with reduced TH-ir in prefrontal and striatal 
brain regions during adolescence. Moreover, hypo activity in adolescent females was not 
affected by ovariectomy, suggesting that reduced activity in adolescent females is not 
caused by differences in circulating gonadal hormones. Thus, further studies of 
differences in sensitivity after acute drug treatment and rapid drug -induced neural 
plasticity in adolescence may help explain increased sensitivity to drug abuse during this 
period of development. 
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RATIONALE FOR STUDY 2 
In study 1, I argued that the locomotor hypo activity to amphetamine during 
adolescence may reflect a higher response threshold for adolescent than for adult rats, 
given that hypo activity was reduced with a second injection of 0.5 mglkg of 
amphetamine and eliminated with administration of a higher (1.5 mglkg) dose of 
amphetamine. The threshold and the intensity of psycho stimulant responses are 
detennined by the mesocorticolimbic dopamine system (Pierce & Kalivas, 1997) and 
results of study 1 found that adolescent rats had less tyrosine hydroxylase than adults in 
key components of this system, including the nucleus accumbens and the medial 
prefrontal cortex. The nucleus accumbens is the principal site for initiating the locomotor 
activating effects of amphetamine (e.g., Sellings & Clarke, 2003), which suggests that the 
ongoing development of this region may account for age differences in the locomotor 
activating effects of the fIrst and the second injection of amphetamine in study 1. 
Study 2 was designed to investigate this possibility by addressing two hypotheses. 
First, if age differences in locomotor activating effects of amphetamine reflect 
developmental differences in the nucleus accumbens, then age differences in locomotor 
activity will be observed after injections of amphetamine directly into this region. 
Second, if increased activity to a second injection of systemic amphetamine in study 1 is 
initiated in the nucleus accumbens, then an increase in activity from the first to the 
second injection of amphetamine into the nucleus accumbens will be observed only in 
adolescent rats. Only male rats were included in study 2 because of our finding that the 
pattern of age differences was similar for males and females in study 1, in that both sexes 
were hypoactive only to the lower dose of amphetamine compared to adults. 
CHAPTER 3: HEIGHTENED LOCOMOTOR-ACTN ATING EFFECTS OF 
AMPHETAMINE ADMINISTERED INTO THE NUCLEUS ACCUMBENS IN 
ADOLESCENT RATS 
Abstract 
Enhanced risk for drug abuse in adolescence has been associated with developmental 
changes in the nucleus accumbens (NAc), which is associated with addictive and 
locomotor activating effects of psycho stimulants, but studies of targeted drug injection 
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into the developing NAc are lacking. Rats were given injections of amphetamine (0, 3, or 
6 J-lglside) directly into the NAc in early (postnatal day 30; P30) or late (P45) 
adolescence, or in adulthood (P75) and locomotor activity was recorded during two 1 h 
sessions, 48 h apart. Amphetamine increased locomotor activity at all ages. P30 rats were 
more active than adults only at the 6 J-lglside dose, whereas P45 were more active than 
adults only at the 3 J-lglside dose, indicating that locomotor response magnitude is highest 
on P30 and sensitivity to low amphetamine doses is highest on P45. Heightened 
sensitivity of the NAc to amphetamine is consistent with increased risk for addiction 
during adolescence. 
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Introduction 
In people, risk for drug abuse and addiction is higher during adolescence 
compared to any other age group, with adolescents exhibiting higher rates of drug abuse 
and faster transition from drug use to addiction compared to adults (reviewed Spear, 
2000; Wu & Schlenger, 2003a). Increased risk for drug abuse has been associated with 
greater sensitivity to rewarding and reduced sensitivity to aversive effects of 
psycho stimulants in adolescents than in adults (Ernst & Fudge, 2009; Ernst et aI., 2009). 
Differences in psycho stimulant sensitivity also are found in adolescent rodents, which 
exhibit higher sensitivity to rewarding and reduced sensitivity to aversive effects of drugs 
compared to adults (Badanich et aI., 2006; Brenhouse, Sonnteg, & Andersen, 2008; 
Infurna & Spear, 1979; Schramm-Sapyta et at, 2006), suggesting that rodent models of 
adolescence are well suited for investigation of age differences in risk for drug abuse and 
addiction. 
Locomotor activity is a commonly used measure for assessing psycho stimulant 
sensitivity, however there is discrepancy across studies regarding age differences in the 
locomotor-activating effects of psycho stimulants. Whereas higher activity levels are 
found in adolescents than in adults with drugs that block dopamine uptake (e.g., cocaine, 
methylphenidate, and nomifensine), hypoactivity is found in adolescents with drugs that 
enhance locomotor activity by increasing dopamine release (e.g., amphetamine, MDMA) 
(Badanich et aI., 2006; Bolanos et aI., 1998; Mathews, Waters, & McCormick, 2009; 
Walker et aI., 2010). The pharmacological basis for these effects is not well-understood, 
although it has been proposed that pharmacokinetic factors, that is, variation across drugs 
in reaching neural targets, may be an important source of age-specific ~ffects. 
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Pharmacokinetic changes may account for dosage effects, as studies using amphetamine 
have found adolescents to be less active than adults at low drug doses and as active as 
adults at higher doses (Adriani & Laviola, 2000; Bolanos et aI., 1998; Mathews & 
McCormick, 2007; Mathews et aI., 2009). Nevertheless, studies that have examined both 
behavioural and pharmacokinetic effects of psycho stimulants have not found a 
relationship between brain levels of drug and locomotor activity that could explain age 
differences (Frantz et aI., 2006; Spear & Brake, 1983; Zombeck et aI., 2009). Further, 
pharmacokinetic factors do not readily explain the effects of repeated amphetamine 
treatment, whereby adolescents, and not adults, showed a significant increase in 
locomotor activity to a second dose of amphetamine (Mathews et aI., 2009). Further, 
despite initial hyporesponsiveness, adolescents showed evidence of long-lasting 
sensitization to amphetamine that was not found when the same treatment regimen was 
administered in adulthood (Mathews, Kelly, & McCormick, 2010). 
It is likely that age differences in the central nervous system underlie 
developmental differences in drug-related behaviour. Locomotor activating effects of 
amphetamine are associated with amphetamine's actions in the mesocorticolimbic 
dopamine system, which undergoes extensive remodelling in adolescence (reviewed in 
Andersen, 2005; Chambers et aI., 2003; Crews, He, & Hodge, 2007). The mesolimbic 
dopamine system is comprised of dopaminergic projections from the ventral tegmental 
area to the nucleus accumbens (NAc) and the medial prefrontal cortex (mPFC), as well as 
the amygdala and the hippocampus (Fallon, 1988; Lewis & O'Donnell, 2000; Swanson, 
1982). Amphetamine results in prolonged actions of dopamine at post-synaptic targets by 
increasing dopamine release through actions atthe dopamine transport.er (reviewed in 
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Fleckenstein, Volz, Riddle, Gibb, & Hanson, 2007). The NAc is a key structure for 
amphetamine's locomotor activating effects. Lesions of dopamine terminals in the core of 
the NAc block locomotor activating effects of amphetamine (Sellings & Clarke, 2003) 
and injections of amphetamine directly into the NAc are sufficient to produce a robust 
increase in locomotor activity (e.g., Cador, Bjijou, & Stinus, 1995; Dougerty & 
Ellinwood, 1981; Vezina & Stewart, 1990). The NAc undergoes changes in dopamine 
receptor and transporter density, dopamine autoreceptor and dopamine transporter 
sensitivity, changes in basal dopamine and cAMP levels, as well as in dopamine receptor 
coupling to cAMP in adolescence (Andersen, 2002; Andersen, Rutstein, Benzo, 
Hostetter, & Teicher, 1997; Badanich et aI., 2006; Stanwood, McElligot, Lu, & 
McGonigle, 1997; Tarazi & Baldessarini, 2000b; Tarazi, Tomasini, & Baldessarini, 1998; 
Walker et aI., 2010). Nevertheless, it is not clear how these changes relate to age 
differences in sensitivity to amphetamine. 
In adults, much of what is known about effects of psycho stimulants in different 
components of mesocorticolimbic circuitry has been mapped using targeted drug 
injection into specific neural regions. Studies of targeted drug injectionin adolescents are 
lacking. The one study that has used intra-cerebral drug injection for investigation of age 
differences found greater locomotor activity in early adolescent than adult rats to an 
NMDA receptor antagonist delivered directly into the NAc (Frantz & Van Hartesveldt, 
1999b), which suggests that there are functional differences in the NAc that can be 
attributed to developmental differences between adolescents and adults. It is important to 
investigate the developmental differences in the responsiveness of the NAc to drugs of 
abuse, considering its critical role inthe development of drug addictio~ (Nestler, 2005). 
55 
In the present study we investigated whether age differences in the locomotor activating 
effects of amphetamine would be found when delivered directly into the NAc. If age 
differences are observed under these conditions, they likely reflect the maturational status 
of the NAc, and counter the possibility that age differences are simply a reflection of the 
systemic route of administration. 
Method 
Animals 
Long Evans male rats (n = 72) were purchased from Charles River Laboratories 
(St. Constant, QC, Canada) and arrived at our facility on postnatal day 22 (P22), P35, or 
P65. These ages were selected so that by time oftesting, ages would represent early 
adolescence (pre-pubertal, P30), late adolescence (post-pubertal, P45), and adulthood 
(P75) based on the classifications ofTirelli and colleagues (Tirelli et aI., 2003). Rats were. 
housed two per cage until surgery at which point they were singly housed with food and 
water available ad libitum and on a 12 h (lights on at 8 am) light cycle. All experiments 
were in compliance with National Institutes of Health (NIH) and the Canadian Council of 
Animal Care (CCAC) guidelines, and were approved by the Brock University Animal 
Care and Use Committee. 
Surgery 
Rats underwent stereotaxic surgery for bilateral cannulae implantation into the 
core of the nucleus accumbens on P25, P40, or P70. Rats were anaesthetized with a 
ketamine/xylazine mixture and guide cannulae were implanted into the nucleus 
accumbens using age-appropriate coordinates (P70: AP 10.6 from lambda, ML 1.5, and 
DV - 5.8; P25: AP 9.3, ML 1.5, DV, 4.0; P40: AP 9.6, ML 1.5, DV 5.2). Coordinates for 
adult rats were based on the atlas of Paxinos and Watson (paxinos & Watson, 2005) and 
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coordinates for the adolescent groups were detennined from the initial pilot surgeries. 
Guide cannulae, 16 mm in length, were constructed from 23 gauge needles and 
positioned 1 mm above the injection site, such that the injection needle (30 gauge, 17 mm 
in length) protruded 1 mm below the tip of the guide cannulae. Guide cannulae were 
secured in place using stainless-steel jewellery screws and dental acrylic and were 
plugged with removable pins. Rats were given 5 days to recover from surgery before the 
start of testing. 
Locomotor activity 
Locomotor testing was conducted in four white open top square melamine arenas 
(58 cm) under indirect red light illumination to reduce anxiety associated with bright 
lighting. Rats were habituated to the test arena at either P30, P45, or P75, when all rats 
were given a bilateral injection of saline (0.5 /lVside) into the NAc. Injections were 
administered over 1 min with Hamilton constant rate micro syringes (CR 700) that were 
connected to stainless-steel injecting needles by polyethylene PE-l 0 tubing. The injection 
needles were removed after an additional minute to allow for diffusion of vehicle into the 
brain and then rats were placed into the locomotor test arena for 1 h of habituation. 
Testing began 24 h later (test 1) when rats were either P31, P46, or P76. Rats were given 
an injection of either saline (0.5 /lVside) or one of two doses of amphetamine (3 or 6 /lg 
in 0.5 /ll of saline) into each hemisphere before placement into the test arena. Locomotor 
activity was recorded using a Sony video camera mounted from the ceiling and connected 
to a computer tracking system (Smart; Panlab, Spain) that recorded distance traveled in 
cm. The same procedure was repeated 48 h later (test 2), with rats given the same drug 
and dose as on test 1. After testing was completed, rats were given ab!lateral injection of 
0.5 III of 2.5% methylene blue dissolved in saline directly into the NAc to conftrm 
cannulae placements. Brains were sliced into 50 Ilm sections, mounted onto slides, and 
examined under a light microscope for localization of cannulae placements. Only rats 
with both injection sites terminating into the NAc were included in the analyses, except 
for one saline-treated rat at P30 for which one cannula was just above the NAc in the 
caudate nucleus. Injection sites ranged from AP: 11.3 - 10.3; ML: 1.0 - 2.8; DV: 6.0 -
8.0. 
Statistics 
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Analyses were conducted using mixed factor ANOVA (SPSS Inc., Chicago, IL), 
with the between group factors of Age (P30, P45, or P75) and Drug (saline, 3 or 6 
Ilglside of amphetamine) and the within group factor of Test Day (test 1, test 2). The 
sample size for statistical analysis was n = 56. Twelve rats were removed from the 
analyses because one (or both) cannula was outside the NAc core. Another four rats were 
removed from analyses because of technical problems associated with injections. 
Results 
Locomotor activity: Total distance traveled 
An Age (P30, P45, P75) X Drug (0, 3, or 6 Ilglside of amphetamine) X Test Day 
(Test 1, Test 2) ANOVA revealed signiftcant Test Day X Drug (F(2,47) = 5.05, P = 0.01) 
and Age X Drug (F(4,47) = 3.98, p = 0.007) interactions, and an Age X Test Day 
interaction that approached signiftcance (F(2,47) = 2.95, P = 0.06). Post hoc tests found 
that activity decreased from test 1 to test 2 only for rats given 3 Ilglside of amphetamine 
(p = 0.02), although this difference was not signiftcant when each age was analyzed 
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separately. For rats given 6 /lg/side of amphetamine, the decline in activity from test 1 to 
test 2 was significant only for P75 rats (p = 0.003) (see Figure 3.1 a-c). 
Analysis of the Age X Drug interaction revealed a significant effect of dose in 
P30 rats (F(2,13) =22.12, P < 0.0001), with rats given 6 /lg/side of amphetamine 
traveling greater distances than those given either saline (p < 0.0001) or 3 /lg/side of 
amphetamine (p = 0.003). Rats given 3 /lg/side traveled greater distances than those 
given saline (p = 0.01). The effect of dose was also significant on P45 (F(2,l3) = 4.46, P 
= 0.03), with rats given 3 (p = 0.01) or 6 (p = 0.03) /lg/side of amphetamine traveling 
greater distances than those given saline. Rats in the 3 /lg/side group did not differ from 
those in the 6 /lg/side group in P45 rats. The effect of dose was significant for P75 rats 
(F(2,21) = 32.30, P < 0.0001), with rats given 3 (p = 0.02) or 6 (p < 0.0001) /lg/side of 
amphetamine traveling greater distances than those given saline, and rats given 6 /lg/side 
of amphetamine traveling greater distances than rats given 3 flg/side of amphetamine (p = 
0.001) (see Figure 3.1 a-c). 
Age differences were significant for each drug group. For rats given saline 
(F(2,15) = 3.99, p = 0.04), P45 rats traveled greater distances than did P30 rats (p = 0.01). 
There was also a trend for P45 rats to travel more than P75 rats (p = 0.06). For rats given 
3 /lg/side of amphetamine (F(2,14) = 3.93, P = 0.04), P45 rats traveled greater distances 
than P75 rats (p = 0.02), whereas P30 and P75 rats did not differ. For rats given 6 /lg/side 
of amphetamine (F(2,18) = 7.45, P = 0.004), P30 rats traveled greater distances than P75 
rats (p = 0.001), and P45 and P75 rats did not differ (see Figure 3.1 a-c). 
Locomotor activity: Percent change from saline 
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To control for potential effects of baseline differences in locomotor activity, the 
analyses were repeated for the amphetamine groups' activity expressed as the percent 
change from that of saline groups. There was a Day X Dose interaction (P(1, 32) = 7.61, 
P = 0.01), however, post hoc analysis of the percent increase in activity from saline from 
test 1 to test 2 was not significant for either dose of amphetamine. 
The Age X Dose interaction was significant (F2,32 = 4.27, P = 0.02): Rats 
traveled more in the 6 J.1g/side than the 3 J.1g/side groups for P30 rats (t(9) = 3.05, p = 
0.01) and for P75 rats (t(13) = 3.44, P = 0.004), but not for P45 rats. The effect of Age 
did not reach significance for rats given 3 J.1g/side of amphetamine (F(2,14) = 2.19, P = 
0.15) (see Figure 3.1 d). For rats given 6 J.1g/side of amphetamine, the effect of Age was 
significant (F(2,18) = 16.41, P < 0.0001), with P30 rats traveling greater distances than 
P45 (p < 0.0001) and P75 (p < 0.0001) rats (see Figure 3.1, e). 
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Figure 3.1. Mean (±SEM) locomotor activity in rats that were given (a) saline, (b) 3 
flglside of amphetamine, or (c) 6 flglside of amphetamine into the nucleus accumbens. 
Locomotor activity expressed as the percent change from saline for rats given (d) 3 
flglside and (e) 6 flglside of amphetamine is also shown. *p < 0.05. Different letters 
denote a significant difference, p < 0.05. 
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Comparison of locomotor activity after systemic vs. intra-accumbens amphetamine 
To gauge how intra-NAc dosages compare with systemic administration, we 
compared locomotor activity in the present study to previous findings (Mathews et aI., 
2009). For P30 rats, distance traveled after 3 )lg/NAc of amphetamine was not different 
from that after 0.5 mglkg i.p., although the shorter distance traveled after 0.5 mglkg i.p. 
than after 3 )lg/NAc on test 1 approached significance (p = 0.07). Distance traveled after 
6 )lg/NAc was not different from that after 1.5 mglkg i.p. on either test day. For P45 rats, 
distance traveled after 3 or 6 )lg/NAc was higher than after 0.5 mg/kg i.p on both test 
days (both p < 0.05) and was not different from that after 1.5 mglkg i.p. on either test 
day. For P75 rats, distance traveled after 6 )lg/NAc was not different from that after 0.5 
mglkg i.p. and was less than that after 1.5 mglkg i.p. on test 1 (p = 0.06) and on test 2 (p 
= 0.02). In summary, for P30 rats, 3 )lg/NAc = 0.5 mglkg i.p < 6 )lg/NAc = 1.5 mg/kg 
i.p.; for P45 rats, 0.5 mg/kg i.p. < 3 )lg/NAc = 6 )lg/NAc = 1.5 mg / kg; for P75 rats, 3 
)lg/NAc < 0.5 mglkg i.p = 6 )lg/NAc < 1.5 mglkg i.p (see Figure 3.2). 
N. ACCUMBENS INJECTION COMPARED TO I.P. INJECTION 
3 "g/0.5 " I Na, 05 mg/kg IP 6 \.Ig/0.5.\.I1 NAc 1.5 mg/kg IP 
Figure 3.2. Mean locomotor activity for rats given 3 or 6 flglside of amphetamine (P30, 
P45, P75) into the nucleus accumbens compared with locomotor activity for rats given 
0.5 or 1.5 mg/kg of amphetamine, i.p. (P30, P45, P70) collapsed over iwo test days. 
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Discussion 
We used targeted drug delivery into the brain to investigate the role of the nucleus 
accumbens (NAc) in developmental differences in the locomotor activating effects of 
amphetamine. Compared to saline injection, both doses of amphetamine increased 
locomotor activity in all age groups on both test days, as reported previously for adult rats 
(e.g., Cador et aI., 1995; Dougerty & Ellinwood, 1981; Vezina & Stewart, 1990). The 
injection of a higher dose of amphetamine (6 Ilg/side) led to increased locomotor activity 
compared to a lower dose (3 Ilg/side) in both P30 (pre-pubertal, early adolescence) and 
P75 (adult) rats, whereas activity did not differ between the two doses at P45 (mid-
adolescence, post-pubertal). Injections of amphetamine into the NAc have been shown to 
increase locomotor activity dose-dependently within this dose range in adults (e.g., Cador 
et aI., 1995). 
Overall, injection of amphetamine directly into the NAc produced greater 
locomotor activity in adolescent than in adult rats. The higher locomotor activity of P30 
rats compared to P75 rats was significant only with the higher dose, and P30 rats were 
also more active than P45 rats with the higher dose when activity was expressed as the 
percent change from saline. In contrast, P45 rats were more active than adults with the 
lower dose of amphetamine only, and the difference was attenuated when activity was 
expressed as the percent change from saline. These data suggest that the nature of the age 
difference in the NAc changes over stages of adolescence, with the magnitude of the 
locomotor response declining after early adolescence, and sensitivity to lower levels of 
stimulation increasing in late adolescence before declining to adult lev.els. 
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Changes in the locomotor activating effects of amphetamine at different stages of 
adolescence and in adulthood likely reflect developmental changes in the NAc. In the 
NAc, there is a continued rise in dopamine transporter (Tarazi et aI., 1998), and dopamine 
D3 receptor (Stanwood et aI., 1997) density throughout adolescence, and an 
overproduction of dopamine D 1 and D2 receptors that peaks at P40 before declining to 
adult levels (Andersen et aI., 2000; Tarazi & Baldessarini, 2000b). In addition, basal 
dopamine (Badanich et aI., 2006) and cAMP (Andersen, 2002) levels are elevated in 
adolescence, whereas dopamine receptor regulation of cAMP is reduced (Andersen, 
2002) and dopamine autoreceptors (Andersen et aI., 1997) and dopamine transporters 
(Badanich et aI., 2006) function is enhanced in the NAc of adolescent compared to adult 
rats. Results of the present study suggest that the net effect of these developmental 
changes is to raise sensitivity of this region to amphetamine in adolescence compared to 
adulthood. Moreover, age differences in activity cannot be explained by greater diffusion 
of amphetamine in the brains of adolescent than adult rats because P30 rats, which have 
smallest brains, were not more active than adults at the low dose of amphetamine, and 
each age comparison was significant only at one of the two doses. 
The results suggest that there is a rightward shift in the dose-response curve of 
amphetamine in the NAc of adult compared to adolescent rats. We compared locomotor 
activity after intra-accumbal amphetamine to that found after systemic amphetamine in a 
previous study (Mathews et aI., 2009): Systemic administration of 1.5 mglkg 
amphetamine resulted in similar locomotor activity as reported here for 6 J..Lg/side of intra-
accumbal amphetamine in P30 rats and higher activity than that for 6 J..Lg/side in adult 
rats, which indicates that activity after the 6 J..Lg/side dose is not the cei~ing for locomotor 
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activity in adults. Thus, either adults would show increased locomotor activity to an intra-
accumbal dose higher than 6 Ilg/side or the higher activity after 1.5 mglkg amphetamine 
than after 6 Ilg/side of intra-accumbens amphetamine involves actions at other neural 
sites. 
The finding of greater sensitivity of adolescents than adults to intra-accumbal 
amphetamine is in contrast to the reports of hyposensitivity in adolescence to systemic 
doses of amphetamine (Adriani & Laviola, 2000; Bolanos et aI., 1998; Frantz et aI., 2006; 
Mathews & McCormick, 2007; Mathews et aI., 2009; Zombeck et aI., 2009). Others have 
also found that the pattern of age differences in drug-induced behaviour depends on route 
of administration: Adolescents had greater activity than did adults after intra-NAc 
injection of the NMDA receptor antagonist MK-801, whereas adults had greater activity 
than adolescents after systemic injection ofMK-801 (Frantz & Van Hartesveldt, 1999a, 
1999b). In conjunction with our study, these data suggest that developmental differences 
in regulatory regions outside of the NAc contribute to locomotor hypoactivity in 
adolescent rats and to enhanced locomotor activity in adult rats after systemic drug 
administration. We previously found that adolescents, and not adults, had a significant 
increase in activity to a second administration of systemic amphetamine (Mathews et aI., 
2009). Increased locomotor activity to a second dose of amphetamine was not found here 
using intra-accumbal administration, which also suggests that any heightened plasticity in 
adolescents to repeated administration involves sites other than the NAc. For example, 
hippocampal lesions were found to increase locomotor activating effects of amphetamine 
in adolescent rats (Lanier & Isaacson, 1977) and decrease locomotor activating effects of 
amphetamine in adult rats (White, Whitaker, & White, 2006). Develop~ental differences 
in the medial prefrontal cortex have also been hypothesized to contribute to altered 
psycho stimulant sensitivity in adolescence (Ernst et aI., 2009; Spear, 2000), but this 
hypothesis has not been investigated directly. 
Conclusions 
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Results of the present study demonstrate that sensitivity of the NAc to 
amphetamine changes over adolescence, with early adolescent rats (P30) showing the 
greatest locomotor-activating effects of intra-accumbal amphetamine and late adolescent 
rats (P45) exhibiting greater locomotor-activating effects compared to adults to the lower 
dose of amphetamine. Higher sensitivity of the NAc to amphetamine in adolescence than 
in adulthood has important implications for increased risk for drug addiction during this 
period, as actions of psycho stimulants in the NAc are implicated strongly in addictive 
effects of drugs. Moreover, our fmdings provide support for theories of the neural basis 
of motivated behaviour in adolescence (Chambers et aI., 2003; Ernst et aI., 2009), which 
hypothesize that increased sensitivity to reward during adolescence is associated with 
increased sensitivity of the nucleus accumbens to rewarding effects of psychostimulants 
during this period of development. 
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RATIONALE FOR STUDY 3 
In study 2, adolescent rats were more active than adults when amphetamine was 
injected directly into the nucleus accumbens. These results, however, contrast the 
findings of study 1, in which adolescent rats were less active than adults after a systemic 
injection of 0.5, and same as adults after 1.5, mg/kg of amphetamine. Thus, either low 
doses of amphetamine administered peripherally may be less effective at activating the 
nucleus accumbens in adolescents, or age differences in the locomotor activating effects 
of systemic amphetamine involve brain regions other than the nucleusaccumbens. One 
possible neural candidate is the medial prefrontal cortex, given my finding of reduced 
tyrosine hydroxylase expression in the medial prefrontal cortex in adolescent compared 
to adult rats. Thus, the first aim of study 3 was to investigate age differences in 
amphetamine-induced activation of the nucleus accumbens and the medial prefrontal 
cortex in adolescent and adult rats using phosphorylation of CREB and the expression of 
the immediate early gene c-fos as markers of neural activation. 
The second aim of study 3 was to directly test the hypothesis that the medial 
prefrontal cortex regulates amphetamine-induced locomotor activity in an age-specific 
way. Dopamine receptor agonists and antagonists were injected directly into this region 
and the locomotor activating effects of systemic amphetamine were compared in 
adolescent and adult rats. 
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CHAPTER 4: ROLE OF MEDIAL PREFRONTAL CORTEX DOPAMINE IN AGE 
DIFFERENCES IN RESPONSE TO AMPHETAMINE IN RATS: CREB AND FOS 
EXPRESSION, AND LOCOMOTOR ACTIVITY AFTER INTRA-MPFC INJECTIONS 
OF DOPAMINERGIC LIGANDS 
Abstract 
Here we investigate the neural basis for locomotor hypoactivity to amphetamine in 
adolescent compared to adult rats. Rats aged postnatal day 30 (P30), P45 and P75 were 
given amphetamine (0.0, 0.5, or 1.5 mg/kg, i.p.) and phosphorylation ofCREB (pCREB; 
experiment 1) and expression of Fos (experiment 2) were measured. In the nucleus 
accumbens, pCREB and Fos-ir were higher in adolescent than in adult rats, but 
amphetamine and saline treated rats did not differ. In the prelimbic medial prefrontal 
cortex (mPFC), the 1.5 mg/kg dose of amphetamine induced more Fos-ir than the 0.5 
mg/kg dose and saline only in P30 rats. To further investigate the role of this region in 
age differences, in experiment 3 the D1 antagonist SCH 23390 or the D2 antagonist 
raclopride were injected directly into the prelimbic mPFC before a systemic injection of 
1.5 mg/kg of amphetamine. Intra-mPFC D2 antagonist did not differ from intra-mPFC 
saline groups in amphetamine-induced activity, whereas injection ofa D1 receptor 
antagonist reduced amphetamine activity more in P30 than in P45 and P75 rats. In 
experiment 4, using a lower dose of amphetamine (0.5 mg/kg), an intra-mPFC injection 
of a D1 receptor agonist increased locomotor activity in adolescent and decreased activity 
in adult rats. These results suggest that insufficient activation of mPFC D 1 receptors may 
underlie hypoactivity to a low dose of amphetamine and that greater recruitment of D 1 
receptors is required to achieve adult-like locomotor activity at a higher dose. 
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Introduction 
Most drug use is initiated in adolescence (reviewed in Chambers et aI., 2003; 
Spear, 2000), when progression from recreational use to dependence occurs more rapidly 
than in adulthood (Clark et aI., 1998). Initiation of drug use in adolescence is associated 
with more severe dependence in later life than is initiation of drug use in adulthood (e.g., 
Clark et aI., 1998; Estroff, Schwartz, & Hoffmann, 1989; Merline et aI., 2004; Windle et 
aI., 2008), especially in cases where drug use begins in early compared to later stages of 
adolescence (Hawkins et aI., 1997; Yamaguchi & Kandel, 1984). Increased risk for drug 
dependence during adolescence may be attributed in part to age differences in drug 
sensitivity. For example, adolescents report feeling only negligible effects of cocaine at 
first use, which may lead to higher levels of drug intake during adolescence (Laviola et 
aI., 1999; Weiss et aI., 1994). The age differences in sensitivity to psychostimulant effects 
have been attributed to ongoing development of neural substrates that underlie drug 
responding (Chambers et aI., 2003; Ernst et aI., 2009; Spear, 2000). 
Rodent models of adolescence have made important contributions to our 
understanding of age differences in behavioural responses to psychostimulants and of the 
developmental changes in neural substrates that underlie those responses. Addictive 
properties of drugs are associated with their actions in the nucleus accumbens (NAc) 
(Nestler, 2005), a region that is critical for generating reinforcing and locomotor 
activating effects of psycho stimulants (Sellings & Clarke, 2003; Wise & Bozarth, 1987). 
Using locomotor activity as an index of psycho stimulant sensitivity, adolescent rodents 
are typically found to be less sensitive to a first treatment with 0.5 mglkg of amphetamine 
compared to adults (Bolanos et aI., 1998; Mathews & McCormick, 2009). Nevertheless, 
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we found that age differences in activity were eliminated with administration of a higher 
dose (1.5 mglkg) of amphetamine (Mathews & McCormick, 2009), indicating that 
adolescents require more amphetamine to attain adult-like responding. In contrast, when 
amphetamine was administered directly into the NAc, adolescent rats were found to be 
more active than adults (Mathews & McCormick, 2009). These findings suggest that the 
reduced activity in adolescent rats in response to a systemic injection of amphetamine, 
which results in dispersion of the drug throughout the brain, may involve actions of 
amphetamine on regions outside of the NAc that modulate the locomotor activating 
effects of amphetamine. Indeed, the hippocampus was proposed to have an inhibitory 
effect on amphetamine-induced locomotor activity in adolescence based on the finding 
that the locomotor activating effects of systemic amphetamine in adolescent rats was 
enhanced when the hippocampus was lesioned (Lanier & Isaacson, 1977). 
Effects of regulatory regions other than the NAc and hippocampus on locomotor 
activating effects of amphetamine during adolescence have not been investigated. 
Nonetheless, it has been proposed that ongoing development of the medial prefrontal 
cortex (mPFC) may be involved in the differential regulation of psychostimulant 
responding in adolescence compared to adulthood (Ernst et aI., 2009; Spear, 2000). The 
mPFC is a heterogeneous region comprised of cingulate, pre limbic and infralimbic 
subregions that are highly connected to all components of the mesolimbic dopamine 
system, including the NAc (Porrino & Lyons, 2000). The mPFC and the NAc are 
involved in 'approach' toward salient stimuli, which can be manifested as enhanced 
locomotor activity as well as self-administration of, and increased preference for, I 
psycho stimulants (Alleweireldt, Weber, Kirschner, Bullock, & Neisewander, 2002; 
Sanchez, Bailie, Wu, Li, & Sorg, 2003; Wise & Bozarth, 1987). 
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In the mPFC, approach to salient stimuli is associated with D 1 dopamine 
receptors (reviewed in Ernst et aI., 2009), which attain peak density in adolescence 
(Andersen et aI. , 2000). According to the triadic theory of neurobiology of motivated 
behaviour in adolescence (Ernst et aI., 2009), the modulatory role of the mPFC in 
adolescence is slanted more strongly toward goal-directed approach behaviours than it is 
in adulthood, in part because of age differences in D 1 dopamine receptors. The 
distribution of prefrontal D 1 receptors also changes in adolescence, with many of the 
overproduced receptors found specifically on NAc projection neurons in late adolescence 
and on an unidentified group of cells in early adolescent rats (Brenhouse et aI., 2008). In 
adults, a minimal proportion « 5%) of D 1 receptors are localized to glutamatergic 
projection neurons to the NAc, with most Dl receptors found on GABAergic 
interneurons (Brenhouse, Sonntag et aI., 2008; Vincent, Khan, & Benes, 1993). 
In adults, D 1 dopamine receptors in the mPFC are necessary for the expression of 
locomotor activating effects of amphetamine (Hall et aI., 2009), although the potential 
role of mPFC D 1 dopamine receptors for regulating .age differences in amphetamine-
induced locomotor activity has not been investigated. However, the higher resistance to 
extinction of cocaine conditioned place preference in adolescent compared to adult rats 
has been postulated to involve greater effects of D 1 dopamine receptors in the mPFC 
during adolescence (Brenhouse et aI., 2010). In addition, intra-mPFC treatment with a Dl 
receptor agonist in adolescent rats increased conditioned place preference (CPP) for a 
systemically-administered dose of cocaine that did not produce a prefe!,ence on its own, 
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thereby directly implicating mPFC DI receptors in cocaine's effects in adolescents 
(Brenhouse et at, 2008). These studies did not involve direct comparisons ofDI receptor 
agonists and antagonists in adolescent and adult rats however, thus it is not clear to what 
extent the results were age-specific. 
The present experiments were designed to investigate the role ofDI receptor 
activation in age differences in the actions of amphetamine using several different 
approaches. In experiment I, age differences in activation of the NAc and the mPFC were 
investigated by measuring expression of activated cAMP response element binding 
(CREB) protein using western blotting. CREB is a constitutively bound transcription 
factor that regulates amphetamine-induced gene expression when activated by 
phosphorylation at Serl33 through a DI receptor dependent mechanism (Konradi, Cole, 
Heckers, & Hyman, 1994). Based on the finding that adolescent rats are less active than 
adults after 0.5, but not after 1.5 mg/kg of amphetamine (Mathews & McCormick, 2009), 
we hypothesized that adolescent rats would have less CREB phosphorylation than adults 
in the NAc at the 0.5, but not at the 1.5 mg/kg dose of amphetamine. In contrast, we 
hypothesized that a systemic injection of the 1.5 mg/kg dose of amphetamine would 
result in more CREB phosphorylation than the 0.5 mg/kg dose in the mPFC in adolescent 
rats, based on the role of mPFC D I receptors in dose-dependent cocaine place preference 
in adolescents (Brenhouse et at, 2008). This experiment also provided the opportunity to 
investigate age differences in hormonal responses to amphetamine, as amphetamine is 
known to alter concentrations of testosterone and corticosterone in adulthood 
(Budziszewska, laworska-Feil, & Lason, 1996; Tsai et at, 1996), and concentrations of 
these hormones in circulation in tum modulate the behavioural effects .of amphetamine 
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(Forgie & Stewart, 1994b; Piazza et al., 1991). Gonadal and adrenal honnonal systems 
are undergoing maturation in adolescence (reviewed in Kuhn et al., 2010; McConnick et 
al., 2010), but age differences in the regulation of these honnones by amphetamine are 
not well understood. 
In experiment 2, we used immunohistochemistry to measure expression of the 
immediate early gene c-fos, which is dependent on amphetamine-induced dopamine 
release and is regulated by CREB phosphorylation (Konradi et al., 1994; LaHoste, 
Ruskin, & Marshall, 1996; Robertson, Peterson, Murphy, & Robertson; 1989). We also 
extended our analysis of neural regions to different subregions of the mPFC, including 
the Cg1, Cg2 and the prelimbic subregions. In experiments 3 and 4, we directly compared 
the effects ofintra-mPFC injections ofa D1 dopamine receptor agonist and antagonist in 
adolescent and adult rats to detennine whether the effects of these drugs on the locomotor 
activating effects of systemic amphetamine would depend on age. In experiment 3, we 
tested the hypothesis that D1 receptors are involved in regulating the locomotor 
activating effects of the 1.5 mg/kg dose of amphetamine to a greater extent in adolescent 
than in adult rats. In experiment 4, we tested the hypothesis that the reduced locomotor 
activity at the 0.5 mg/kg dose of amphetamine in adolescent rats is associated with 
reduced activation of pre limbic D1 receptors and that an intra-mPFC injection ofa D1 
agonist would increase locomotor activating effects at this dose of amphetamine in 
adolescent rats compared to in adult rats. 
Experiments 1 - 4 
Animals 
Method 
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The experiments used 219 male Long-Evans rats purchased from Charles River 
Laboratories (St. Constant, QC) and arrived at our colony on postnatal day 22 (P22), 
P37±2, or P67±2. These ages were selected so that by time oftesting ages would 
represent early adolescence (pre-pubertal, P30), late adolescence (post-pubertal, P45), 
and adulthood (P75) based on the classifications of Tirelli and colleagues (Tirelli et aI., 
2003). Rats were pair housed in plastic cages (46 cmx24 cmx20 cm) on a standard 
12h:12h light-dark cycle, with lights on at 8 a.m. Food and water were freely available in 
the home cage. All experiments were in compliance with National Institutes of Health 
(NIH) and the Canadian Council of Animal Care (CCAC) guidelines, and were approved 
by the Brock University Animal Care and Use Committee. 
Test arenas (same for experiments 1-4) 
Every effort was made to keep conditions constant across experiments to facilitate 
the applicability of findings with pCREB and Fos-ir in experiments 1 and 2 for 
interpretation of age differences in locomotor activity in experiments 3 and 4. Previous 
studies have found that the pattern of amphetamine-induced immediate early gene 
expression depends on whether testing occurs in the home cage or in a separate chamber 
(Badiani et aI., 1998). Thus, for all experiments, injections occurred outside the home 
cage and rats were kept in chambers used for measurement of locomotor activity. The 
chambers consisted of four white open-top melamine arenas (58 cm X 58 cm X 58 cm) 
that were illuminated indirectly by red light to attenuate anxiety relate~ to bright lighting, 
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and with white noise in the background. Chambers were cleaned with 50% ethanol after 
each session. All experiments were conducted between 0900 and 1700h. 
Experiment 1 Method 
Drug administration 
64 rats were used for experiment 1. On day I (P30, P45, or P75), all rats were 
given an intraperitoneal (i.p.) injection of 0.9% saline before placement into the test arena 
for 1 h of habituation. The next day (P31, P46, or P76), rats were randomly assigned to 
groups that had an i.p. injection of either saline, 0.5 (Amph 0.5) or 1.5 (Amph 1.5) mg/kg 
of amphetamine (n = 6-1 0 rats/group) before placement into the arena for 30 min. Rats 
were euthanized by rapid decapitation immediately after removal from the test arena for 
collection of brain tissue and blood samples (see below). 
Western blotting 
Brains were rapidly removed and a 1 mm section (-10.40 - 11.40 mm from 
lambda according to Paxinos & Watson, 2005) was dissected using stainless steel Brain 
Matrices (coronal with I mm spacers; Ted Pella, Inc.). Tissue punches (1.19 mm) were 
taken from the core and shell of the NAc and from the Cgl subregion of the mPFC. 
Samples were homogenized in lysis buffer and centrifuged for 10 min at 16,000g. The 
pellet was discarded and the supernatant was dissolved in equal volume of Lammeli 
buffer (buffer solutions adapted from Konradi, 2003), heated for 5 min at 70°C, and 
centrifuged again for 10 min at 16,000g. Samples were resolved using 12% SDS-PAGE 
and transferred to PVDF membrane (Millipore). Membranes were reversibly stained 
using Ponceau-S (Sigma-Aldrich) for determination oftotal protein for use as a loading 
control (Aldridge, Podrebarac, Greenough, & Weiler, 2008). The mem~ranes were 
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blocked in 5% BSA in TBS-T for I h at room temperature and probed with pCREB 
primary antibody (1:1000; Abcam) dissolved in TBS-T overnight at 4°C. Membranes 
were washed thoroughly with TBS-T and incubated in Alexa Fluor 488 (Invitrogen) 
secondary antibody (1:5000) for 45 min at room temperature. Membranes were washed 
and imaged wet using the VersaDoc Imaging System (Bio-Rad). Staining intensity 
(intensity X rom) of each band was analyzed using the Quantity One imaging program for 
the Versa Doc (Bio-Rad). 
Enzyme-linked immunosorbent assay (ELISA) 
Trunk blood was collected in ice-chilled tubes containing EDT A. Samples were 
centrifuged at 3000 rpm for 10 min and plasma was collected and stored at -20°C for later 
analysis with ELISA kits. Samples were prepared and analyzed according to kit 
instructions for corticosterone (Neogen Corporation, #402810) and testosterone (Neogen 
Corporation, #402510). Briefly, steroid hormones were extracted using N2, diluted in 
extraction buffer, and assayed in duplicate using the appropriate kit. Plates were read at 
650 nm using a Synergy HT microplate reader (Bio-Tek). Typical intra- and inter-assay 
CV for these kits is ::::: 10%. 
Statistics 
Analyses of corticosterone and testosterone concentrations were conducted using 
factorial ANOV A with the between-group factors of Age (P30, P45, P75) and Drug 
(Saline, Amph 0.5, Amph 1.5). One animal was dropped from the analysis because of a 
technical error in sample preparation. Analyses for phosphorylated CREB (PCREB) were . 
conducted using factorial ANOV A with the between-group factors of Age (P30, P45, 
P75) and Group (Saline, Amph 0.5, and Amph 1.5). Only brains with ~ufficient protein 
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concentrations were used for analysis, which resulted in 4 to 8 animals in each group. 
Post-hoc analyses were conducted using F-tests for simple effects and Fisher's protected 
least squares difference tests. 
Experiment 1 Results 
Endocrine measures 
Testosterone. There was an effect of Age on plasma testosterone concentrations 
(F(2,45) = 21.87, P < 0.0001): P75 rats had higher concentrations than P30 and P45 rats 
(both p < 0.0001) and P45 had higher concentrations than P30 (p = 0.04) rats (see Figure 
4.1 a). There was no effect of drug or interaction of age and drug. 
Corticosterone. For plasma corticosterone, there was an effect of Age (F(2,44) = 
7.07, P = 0.002), an effect of Drug (F(2,44) = 11.85, P < 0.0001), and no interaction. P45 
rats had higher corticosterone concentrations than P30 (p = 0.008) and P75 (p = 0.001) 
rats. Rats in the Amph 1.5 group had higher corticosterone concentrations than rats in the 
Saline (p = 0.001) and Amph 0.5 (p < 0.0001) groups. Rats in the Amph 0.5 group did 
not differ from rats in the Saline group (see Figure 4.1 b). 
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Figure 4.1. Mean (±SE.M) plasma (a) testosterone and (b) corticosterone concentrations 
in P30, P45 and P75 rats 30 min after treatment with saline or amphetamine (0.5 or 1.5 
mg/kg). Matched letters indicate a significant group difference. 
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cAMP response element binding (CREB) protein phosphorylation 
Nucleus accumbens. For pCREB in the NAc core, there was an effect of Age only 
(F(2,39) = 7.28, P = 0.002): P75 had lower pCREB than P30 (p = 0.001) and P45 (p = 
0.005) rats, and P30 and P45 rats did not differ (see Figure 2 a). In the shell, there an 
effect of Age (F(2,40) = 4.48, P = 0.02) only: P45 rats had higher pCREB than P30 rats 
(p = 0.008) and there was a trend for higher pCREB for P45 than for P75 rats (p = 0.07) 
(see Figure 4.2 b). 
Medial prefrontal cortex (CgJ). For pCREB in the mPFC, there an effect of Age 
(F(2,43) = 5.42, P = 0.008) and an Age X Drug interaction (F(4,43) = 3.11, P = 0.03). An 
effect of Age (F(2,12) = 4.67, P = 0.03) was found for rats in the Saline group: P30 rats 
had higher pCREB than P45 (p = 0.05) and P75 (p = 0.01) rats. An effect of Age (F(2,13) 
= 4.07, P = 0.04) was found for rats in the Amph 1.5 group: P30 rats had higher pCREB 
than P75 rats (p = 0.01) and there was a trend for higher pCREB in P45 than in P75 rats 
(p = 0.07) rats (see Figure 4.2 c). Age differences were not found for rats in the Amph 0.5 
group. 
For P30 rats, the effect of Drug (F(2,17) = 6.67, P = 0.007) was that rats in the 
Amph 0.5 group had lower pCREB than rats in the Saline (p = 0.004) and Amph 1.5 (p = 
0.02) groups (see Figure 4.2 c). For P45 and P75 rats, the effect of Drug was not 
significant. 
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Figure 4.2. Mean (±SEM) staining intensity for pCREB in the (a) nucleus accumbens 
core, (b) nucleus accumbens shell, and (c) the medial prefrontal cortex; #Higher than 0.5 
mg/kg (p < 0.05). Same letters indicate a significant group difference. 
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Experiment 1 Discussion 
Overall, adolescent rats were found to have lower basal concentrations of 
testosterone and higher basal concentrations of corticosterone than adult rats, 
amphetamine did not have age-specific effects on the release of either honnone, and 1.5 
mg/kg amphetamine increased corticosterone concentrations in all age groups. These 
results are consistent with previous reports of the progressive rise in testosterone through 
puberty (Korenbrot, Huhtaniemi, & Weiner, 1977) and with findings in adult rats of 
enhanced corticosterone release only with doses higher than 0.5 mg/kg (Swerdlow, Koob, 
Cador, Lorang, & Hauger, 1993). 
The only effect of drug group on pCREB was in the mPFC in P30 rats, whereby 
the lower pCREB was found for rats that had 0.5 mg/kg compared to 1.5 mg/kg 
amphetamine and saline. Amphetamine did not increase pCREB at any dose in the NAc, 
indicating that CREB phosphorylation is not sensitive enough for detecting drug effects 
at these doses. Overall pCREB, however, was higher in adolescent than in adult rats in 
all regions. These findings are consistent with reports of a higher dopaminergic tone in 
the NAc and the mPFC during adolescence, as evidenced by higher basal levels of cAMP 
(Andersen, 2002) and greater dopamine receptor density (Andersen et aI., 2000) in 
adolescent compared to adult rats. 
In experiment 2 we investigated age differences in amphetamine-induced neural 
activation of the NAc and the mPFC using Fos, the protein product of the immediate 
early gene, c-fos. Although Fos expression is strongly associated with phosphorylation of 
CREB by amphetamine (C. Konradi et aI., 1994), Fos-ir is not always correlated with 
pCREB (e.g., Shiromani, Magner, Winston,& Chamess, 1995; Turge~n, Pollack, & 
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Fink, 1997), and F os-ir was found to increase in response to acute amphetamine even 
when pCREB did not change (Turgeon et aI., 1997), indicating that c-Fos may allow for 
improved detection of amphetamine actions in the brain. We also extended the neural 
regions examined to include the pre limbic subregion as it may be more responsive to 
psychostimulant treatment than the Cg1 region (Mazei, Pluto, Kirkbride, & Pehek, 2002). 
Method Experiment 2 
Drug administration 
54 rats were used for Experiment 2. On day 1 (P30, P45, or P75), all rats were 
given an i.p. injection of 0.9% saline before placement into the test arena for 1 h of 
habituation. The next day (P31, P46, or P76), rats were randomly assigned (n = 6 
rats/group) to intraperitonal injection groups of either saline, 0.5 (Amph 0.5) or 1.5 
(Amph 1.5) mg/kg of amphetamine before placement into the arena for 1 h. 
Immunohistochemistry 
After removal from the test arena, rats were deeply anesthetized and transcardially 
perfused with 4% paraformaldehyde in O.lM phosphate buffer (PH 7.4). Brains were 
placed in a 30% sucrose and paraformaldehyde solution until they sank. Coronal sections 
(40 Jlm thick) were collected throughout the mPFC, including the prelimbic (~11.7 - 12.7 
mm from lambda according to Paxinos and Watson (2005) and cingulate cortex area 1 
and 2 (Cg1 and Cg2) subregions, and the NAc core and shell (~l 0.4 - 11.4 mm from 
lambda according to Paxinos and Watson (2005) using a cryostat (ThermoShandon). 
Every fourth section was collected for the prelimbic region and every sixth section was 
collected from the remaining regions for immunohistochemistry, resulting in a total of 
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four sections within each set of coordinates. The sections were stored in cryoprotectant at 
-20°C until the immunohistochemistry was performed. 
Free floating sections were washed stringently in PBS with 0.2% Triton X (PBSx, 
pH 7.4), then in 0.3% hydrogen peroxide, and then again in PBSx. Next, the tissues were 
incubated for 24 hr at 4°C in 1 % NGS and Fos primary antibody diluted at 1 :2000 (Santa 
Cruz). After incubation, the sections were washed three times in PBSx before incubation 
for 75 min in biotinylated anti-rabbit immunoglobulin secondary antibody (Vector 
Laboratories) diluted at 1 :300 (Vector Laboratories). The sections were again washed in 
PBSx and placed for 30 min in Avidin-Biotin Complex (Vector Laboratories). After 
another three washes in PBSx, tissues were placed in diaminobenzidine solution 
according to the instructions on the substrate kit (DAB SK-4100, Vector Laboratories) 
for 5 min. Immunostained sections were mounted onto slides, dried, and coverslipped 
with Permount. Sections for the mPFC (prelimbic, Cgl, Cg2) were photographed at 200X 
magnification and NAc core and shell at 400X magnification with a Nikon Eclipse 
brightfield microscope and all stained cells were counted. The same size area was 
counted for all regions and for all ages at 200X (500 /lm X 500 /lm)and 400X (250 /lm 
X 250 /lm) magnification. Measures for each structure were averaged across hemispheres 
and sections, and rats for which there were fewer than three measures for a structure were 
excluded, resulting in n = 5±1 for each brain region and for each group. 
Statistics 
Factorial ANOVAs were conducted for each brain region separately, with the 
between group factors of Age (P30, P45, P75) and Drug (Saline, Amph 0.5, Amph 1.5). 
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Post-hoc analyses were conducted using F-tests for simple effects and Fisher's protected 
least squares difference tests . . 
Experiment 2 Results 
Nucleus accumbens (NAc) 
Core. For Fos-ir cell counts in the NAc core, there was an effect of Age (F(2,43) 
= 3.58, p = 0.04) and an effect of Drug (F(2,43) = 4.21, p = 0.02). P30 rats had more Fos-
ir cells than P75 rats (p = 0.006) and there was a trend for more Fos-ir cells in P30 
compared to P45 rats (p = 0.06) (see Figure 4.3 a). Rats in the Amph L5 group had more 
Fos-ir cells than rats in the Amph 0.5 group (p = 0.005) (see Figure 4.3 a). 
Shell. For Fos-ir cell counts in the NAc shell, there was a significant Age X Drug 
interaction (F(4,42) = 2.58, p = 0.05). Follow-up analyses found an effect of Age (F(2,15) 
= 5.12, P = 0.02) only in the Saline group: P45 rats had more Fos-ir cells than P30 (p = 
0.05) and P75 (p = 0.007) rats (see Figure 4.3 b). 
For P30 rats, the effect of Drug approached significance (F(2,13) = 3.59, p = 
0.057): rats in the Amph 1.5 group had more Fos-ir cells than rats in the Amph 0.5 group 
and rats in the Amph 1.5 group had more Fos-ir cells than rats in the Saline group (p = 
0.06). For P45 and P75 rats, the effect of Drug was not significant. 
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Figure 4.3. Mean (±SEM) number of Fos-ir cell counts for the nucleus accumbens (a) 
core and (b) shell; *Higher than Amph 0.5 (p = 0.03). Same letters indicate a significant 
difference. 
Medial prefrontal cortex (mPFC) 
Prelimbic. For Fos-ir cell counts in the prelimbic cortex, there was a main effect 
of Drug (F(2,40) = 6.43, p = 0.004) and an Age X Drug interaction (F(4,40) = 2.78, P = 
0.04). Follow-up analyses did not find an effect of Age at any dose. For P30 rats, the 
effect of Drug (F(2,12) = 7.00, P = 0.01) was that rats in the Amph 1.5 group had more 
Fos-ir cells than rats in the Saline (p = 0.004) and Amph 0.5 (p = 0.01) groups. For P45 
and P75 rats, the effect of Drug was not significant (see Figure 4.4 a). 
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Cgl. For Fos-ir cell counts in Cgl, there was an effect of Age only (F(2,40) = 
6.45, P = 0.004): P30 rats had more Fos-ir cells than P45 (p = 0.002) and P75 (p = 0.01) 
rats (see Figure 4.4 b). 
Cg2. For Fos-ir cell counts in Cg2, there was an interaction of Age and Drug 
(F(4,40) = 2.95, p = 0.03). An effect of Age (F(2,13) = 5.27, p = 0.02) was found only for 
rats in the Amph 0.5 group, with P75 having more Fos-ir cells than P30 (p = 0.02) and 
than P45 (p = 0.01) rats (see Figure 4.4 c). For P30 rats, follow-up analyses found that the 
effect of Age approached significance (F(2,13) = 3.48, p = 0.06): Rats in the Amph 1.5 
group had more Fos-ir cells than rats in the Saline and Amph 0.5 groups. The effect of 
Drug was not significant for P45 or P75 rats. 
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Figure 4.4. Mean (±SEM) number of Fos-ir cell counts in the (a) prelimbic, (b) Cg1, and 
(c) Cg2 regions of the medial prefrontal cortex. *Amph 1.5 > Saline a1}d A mph 0.5. Same 
letters indicate a significant group difference. 
Experiment 2 Discussion 
As for pCREB, findings with Fos-ir are consistent with a higher overall 
dopaminergic tone in adolescent compared to adult rats in the NAc and the Cgl 
subregion of the mPFC. Fos-ir in the NAc was somewhat more sensitive to drug effects 
than was pCREB, as evidenced by higher Fos-ir in rats that had 1.5 compared to 0.5 
mg/kg of amphetamine. However, the difference in Fos-ir between amphetamine and 
saline did not reach significance, indicating that Fos-ir in the NAc alone cannot account 
for age differences in locomotor activity. 
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Although the locomotor activating effects of amphetamine necessarily involve 
actions in the NAc (Sellings & Clarke, 2003), amphetamine-induced activation of 
dopamine receptors in the mPFC also regulates locomotor activity (Hall et aI., 2009; 
Tzschentke & Schmidt, 2000). In the present study, we found that the 1.5 mg/kg dose of 
amphetamine induced more Fos-ir compared to the 0.5 mg/kg dose and to saline in the 
prelimbic and Cg2 subregions of the mPFC only in P30 rats. The rmding that the high 
dose of amphetamine increased Fos-ir only in P30 rats is consistent with the hypothesis 
that the mPFC has greater control over behaviour in adolescence than in adulthood (Ernst 
et aI., 2009). These findings suggest that the prelimbic mPFC may be more strongly 
involved in regulating locomotor activity in P30 than in P45 and adult rats at the 1.5 
mg/kg dose of amphetamine. Prelimbic D 1 dopamine receptors are particularly relevant 
for locomotor activating effects of amphetamine (Hall et aI., 2009), which undergo 
changes in density and localization in the prelimbic mPFC in adolescence (Andersen et 
aI., 2000; Brenhouse, Sonntag et aI., 2008), indicating that the prelimbic mPFC may exert 
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greater control over locomotor activating effects of amphetamine in P30 rats specifically 
through D 1 dopamine receptors. 
Experiment 3 was designed to directly investigate the hypothesis that prelimbic 
Dl dopamine receptors would contribute more to locomotor activating effects of 1.5 
mg/kg of amphetamine in P30 than in older rats by injecting a D I receptor antagonist 
directly into the pre1imbic mPFC before a systemic injection of amphetamine. We also 
injected a D2 receptor antagonist into the prelimbic mPFC to investigate potential 
differences in contribution of these receptors to locomotor activity, as D2 receptors also 
undergo developmental changes in adolescence (Andersen et aI., 2000). 
Method Experiment 3 
Surgery 
Rats underwent stereotaxic surgery, for bilateral cannulae implantation into the 
pre1imbic region of the mPFC on P25, P40, or P70. Rats were anaesthetized with a 
ketamine/xylazine mixture and guide cannulae were implanted into the pre limbic mPFC 
using age-appropriate coordinates (p70: AP 12.3 from lambda, ML 0.9, and DV 1.8; P25: 
AP 10.9, ML 0.9, DV 0.7; P40: AP J 1.5, ML 0.9, DV 1.5). Coordinates for adult rats 
were based on the atlas of Paxinos and Watson (paxinos & Watson, 2005) and 
coordinates for the adolescent groups were determined from the initial surgeries. Guide 
cannulae, 13 mm in length, were constructed from 23 gauge needles and positioned 1 mm 
above the injection site, such that the injection needle (30 gauge, 14 mm in length) 
protruded 1 mm below the tip of the guide cannulae. Guide cannulae were secured in 
place using stainless-steel jewellery screws ' and dental acrylic and were plugged with 
removable pins. Rats were given 5 days to recover from surgery before the start of 
testing. 
Drug administration 
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47 rats were used for Experiment 3. Rats were given a bilateral injection of saline 
(0.5 IlVside) into the prelimbic mPFC and then were habituated to the test arena for 1 h 
on either P30, P45, or P75. Injections were administered over 1 min with Hamilton 
constant rate micro syringes (CR 700) that were connected to stainless-steel injecting 
needles by polyethylene (PE-IO) tubing. The injection needles were removed after an 
additional minute to allow for diffusion of vehicle into the brain and then rats were 
placed into the locomotor test arena for 15 min. After 15 min, rats were given an intra-
peritoneal injection of saline and were placed back into the test arena for 1 h of 
habituation. D1 (SCH 23390; Sigma-Aldrich) and D2 (raclopride; Sigma-Aldrich) 
dopamine receptor antagonists were administered in counterbalanced order over 2 test 
days within a dose range that was previously found to regulate drug responses when 
administered in the CNS (D Hall et aI., 2009; Samson & Chappell, 2003). During the ftrst 
test day (P31, P46, or P76), rats were given an injection of either saline (0.5 IlVside), the 
D1 receptor antagonist, SCH 23390 (1.0 Ilg in 0.5 III of saline; SCH 1.0) or the D2 
receptor antagonist, raclopride (1.0 Ilg in 0.5 III of saline; Racl 1.0) into each hemisphere 
immediately before placement into the test arena for 15 min. After 15 min, all rats were 
given an intra-peritoneal injection of 1.5 mg/kg of amphetamine (Amph 1.5) and were 
placed back into the test arena for 1 h. The procedure was repeated 48 h later, except that 
animals that had raclopride on the ftrst day had SCH 23390 on the second day and vice 
versa. Locomotor activity was recorded for the ftrst 15 min after intra-~FC drug 
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injection to determine potential effects of antagonists on baseline locomotor activity and 
for the 1 h after intra-peritoneal amphetamine injection to determine effects of 
antagonists on amphetamine-induced locomotor activity. Locomotor activity was 
recorded using a Sony video camera mounted from the ceiling and connected to a 
computer tracking system (Smart; Panlab, Spain) that recorded distance traveled in cm. 
After testing was completed, rats were given a bilateral injection of 0.5 J.1l of 2.5% 
methylene blue dissolved in saline directly into the prelimbic mPFC to confirm cannulae 
placements. Brains were sliced into 50 J.1m sections, mounted onto slides, and examined 
under a light microscope for localization of cannulae placements. Only rats with both 
injection sites terminating in the prelimbic mPFC were included in the analyses. Injection 
sites ranged from AP: 13.2 - 11.5; ML: 0.2 - 1.0; DV: 2.8-3.8. This resulted in the 
removal of 6 rats from the analysis because of incorrect cannulae placement. 
Statistics 
Locomotor activity was analyzed with factorial ANOV A with the between group 
factors of Age (P30, P45, P75) and mPFC Drug (Saline, SCH 1.0 or Racl1.0). Given the 
counterbalanced design, in which the same rats were used for investigation of intra-
mPFC SCH 23390 and raclopride, locomotor activity for each drug was subjected to 
separate factorial ANOV A after confirming that there were no order effects of drug 
administration. Additional analyses were conducted to estimate the effect ofintra-mPFC 
drug injection specifically on the locomotor activating effects of amphetamine by 
calculating a difference score, for which activity for rats in the SCH 1.0 and Racl 1.0 
groups was subtracted from activity for rats in the Saline group. The difference score for · 
each drug (SCH 1.0, Rac11.0) was analyzed by one-way ANOV A with Age (P30, P45, 
P75) as the between-subjects factor. 
Experiment 3 Results 
Did the effect ofintra-mPFC D1 dopamine receptor antagonist SCH 23390 depend on 
age? 
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Baseline activity. For locomotor activity during the first 15 min of testing, there 
was an effect ofmPFC Drug (F(1,35) = 7.49, p = 0.01) only, with rats in the mPFC-SCH 
1.0 group moving less than rats in the mPFC-Saline group (see Figure4.5 a). 
There was no age difference in the degree of inhibition (mPFC-Saline - mPFC 
SCH 1.0) produced by mPFC-SCH 1.0 (see Figure 4.5 b). 
Activity after a systemic injection of 1.5 mg/kg amphetamine. Locomotor activity 
after amphetamine was lower for rats in the mPFC-SCH 1.0 group than for rats in the 
mPFC-Saline group (F(2,35) = 41.84, P < 0.0001). The interaction of Age X mPFC Drug 
approached significance (F(2,35) = 3.05, P = 0.06). Follow-up analyses confirmed that 
rats in the mPFC-SCH 1.0 group had lower activity than rats in the mPFC-Saline group at 
all ages (all p < 0.02). An age difference was not found for rats in the mPFC-Saline 
group. For rats in the mPFC-SCH 1.0 group, there was an effect of Age (F(2,27) = 3.55, P 
= 0.04): P75 were more active than P30 rats (p = 0.02) and there was a trend for greater 
activity for P75 than for P45 (p = 0.06) rats (see Figure 5c). 
SCH 1.0 inhibited locomotor activity (F(2,26) = 9.98, P = 0.001) to a greater 
degree (mPFC-Saline - mPFC SCH 1.0) in P30 than in P45 (p< 0.0001) and P75 (p = 
0.001) rats (see Figure 4.5 d). 
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Figure 4.5. (a) Mean (±SEM) distance traveled in a 15 min baseline (pre-amphetamine) 
immediately after an intra-mPFC irifection of saline, the D1 antagonist SCH 23390, or 
the D2 antagonist raclopride; (b) Mean (±SEM) reduction in distance traveled relative to 
saline after administration of SCH 23390 and of raclopride in the 15 min baseline; (c) 
Mean (±SEM) distance traveled after i.p. irifection of 1.5 mg/kg of amphetamine; (d) 
Mean (±SEM) reduction in distance traveled in SCH 23390 and raclopride groups 
relative to saline after i.p. irifection of 1.5 mg/kg amphetamine. *Main effect of dose; 
Same letters indicate a significant group difference. 
Did the effect of intra-mPFC D2 dopamine receptor antagonist raclopride depend on 
age? 
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Baseline activity. For locomotor activity in the first 15 min after intra-mPFC 
injection, the effect ofmPFC Drug approached significance (F(1,35) = 3.66, P = 0.06), 
with rats in the mPFC-Raclopride group moving less than rats in the mPFC-Saline group 
(see Figure 4.5 a). 
Intra-prelimbic injection of raclopride (F(2,26) = 8.09, p = 0.002) produced a 
greater degree of inhibition in P30 than in P45 (p = 0.001) and P75 (p = 0.003) rats (see 
Figure 4.5 b). 
Activity after a systemic injection of 1.5 mg/kg amphetamine. Raclopride did not 
reduce amphetamine-induced locomotor activity compared to saline at any age (see 
Figure 4.5 c and d). 
Experiment 3 Discussion 
In experiment 2, we found that the 1.5 mglkg dose of amphetamine induced a 
sharp increase in Fos-ir compared to the 0.5 mglkg dose and to saline in the prelimbic 
subregion of the mPFC only in P30 rats. We hypothesized that this increased activation in 
P30 rats reflects greater contribution of pre limbic Dl dopamine receptors to locomotor 
activating effects of 1.5 mg/kg amphetamine compared to older rats because prelimbic 
Dl receptors are thought to have greater control over behaviour in adolescence (Ernst et 
aI., 2009) and because D 1 receptors regulate locomotor activating effects of amphetamine 
in adults (D Hall et at, 2009). Consistent with this hypothesis, we found that an intra-
mPFC injection of a Dl receptor antagonist inhibited amphetamine-induced locomotor 
activity to a greater extent in P30 than in P45 and adult rats, indicating. that prelimbic Dl 
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receptors are more involved in regulation of locomotor activity at the 1.5 mglkg dose in 
early adolescence than in adulthood. Age differences were not found for P45 and adult 
rats, which suggests that the regulation of amphetamine-induced activity by pre limbic D 1 
dopamine receptors may stabilize by late adolescence. In addition, D2 dopamine 
receptors did not affect amphetamine-induced activity at any age, indicating that 
developmental differences in D2 receptors may be less relevant for the locomotor 
activating effects of amphetamine at the doses used in the present study. 
The data from experiment 3 suggest that P30 rats are more dependent on D1 
receptor stimulation for expression of an adult-like locomotor response to 1.5 mglkg 
amphetamine. Thus, our previous observation that adolescent rats are less active than 
adults at the 0.5 mglkg dose (Mathews & McCormick, 2009) may reflect reduced 
activation of pre limbic D 1 dopamine receptors at this dose. Experiment 4 was designed to 
test the hypotheses that the reduced locomotor activating effects of 0.5 mglkg of 
amphetamine in adolescent compared to adult rats involve reduced activation ofD1 
dopamine receptors, and that intra-mPFC injection of a D1 dopamine receptor agonist 
would enhance the locomotor activating effects of a lower dose of amphetamine in 
adolescent rats. 
Method Experiment 4 
Drug administration 
54 rats were used for Experiment 4. Surgeries were conducted as in experiment 3, 
exceptthat P45 rats were not included. Rats were habituated to the test arena at either 
P30 or P75, when all rats were given a bilateral injection of saline (0.5 l.tI/side) into the 
prelimbic mPFC. Injections were administered as in experiment 3. Rat~ were placed into 
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the locomotor test arena for 15 min. After 15 min, rats received an intra-peritoneal 
injection of saline and were placed back into the test arena for 1 h of habituation. On the 
test day (P31, P76), rats were given an injection of either saline (0.5 J.ll/side), D 1 
dopamine receptor antagonist SCH 23390 (1.0 J.lg in 0.5 J.ll of saline; SCH 1.0; Sigma) or 
one of two doses (0.5 or 1.0 J.lg in 0.5 J.ll of saline; SKF 0.5 and SKF 1.0, respectively) of 
the Dl dopamine receptor agonist SKF 81297 (Sigma; doses based on Brenhouse et aI., 
2008) into each hemisphere before placement into the test arena for 15 min. After 15 min, 
all rats were given an intra-peritoneal injection of 0.5 mg/kg of amphetamine (Amph 0.5) 
and were placed back into the test arena for 30 min. Locomotor activity was recorded for 
the first 15 min after intra-mPFC drug injection and for the 30 min after intra-peritoneal 
amphetamine injection as in experiment 3. Localization of cannulae placements was as in 
experiment 3. Only rats with both injection sites terminating into the prelimbic were 
included in the analyses. Injection sites ranged from AP: 13.2 - 11.5; ML: 0.2 - 1.0; DV: 
2.8-3.8. This resulted in removal of6 rats from the analysis because of incorrect 
cannulae placement. An additional rat was removed because of an injection problem. 
Statistics 
Locomotor activity was analyzed with factorialANOVA with the between group 
factors of Age (P30, P75) and mPFC Drug (Saline, SCH 1.0, SKF 0.5, SKF 1.0). 
Experiment 4 Results 
Baseline activity {First 15 min after intra-PFC irifection}. For locomotor activity 
in the first 15 min after intra-mPFC injection, there was an effect ofmPFC Drug (F(3,39) 
= 6.08, P = 0.002) only: ·Rats in the mPFC-SCH 1.0 group were less active than rats in the 
mPFC-Saline(p < 0.0001), mPFC-SKF 0.5 (p =0.003), and SKF 1.0 (p = 0.005) groups; 
Intra-mPFC injection of SKF 0.5 or SKF 1.0 did not affect baseline activity (see Figure 
4.6 a). 
Locomotor activity was inhibited to a greater degree (mPFC-Sal- mPFC-
agonist/antagonist) for rats in the mPFC-SCH 1.0 group than for rats in the mPFC-SKF 
0.5 (p = 0.002) and mPFC-SKF 1.0 (p = 0.003) groups (F(2,30) = 7.68, P = 0.002). The 
effect of age was not significant (see Figure 4.6 b). 
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Activity after a systemic injection 010.5 mg/kg amphetamine. For locomotor 
activity after amphetamine, there was an effect ofmPFC drug (F(3,39) = 16.25, P < 
0.0001) and an Age X mPFC Drug interaction (t(9) = 3.63, p = 0.005). An age difference 
was found for the mPFC-Saline group (F(1,9) = 13.18, P = 0.005), with P75 rats moving 
more than P30 rats. An age difference was found also for rats in the SCH 1.0 group (t(11) 
= 2.46, P = 0.03), with P75 rats moving more than P30 rats. Age differences were not 
found for rats treated with SKF 0.5 of SKF 1.0 (see Figure 4.6 c). 
For P30 rats, there was an effect ofmPFC Drug (F(3,18) = 21.13, P < 0.0001): 
Rats in the mPFC-Saline group were more active than rats in the mPFC-SCH 1.0 group 
(p < 0.0001) and less active than rats in the mPFC-SKF1.0 group (p = 0.05). Rats in the 
mPFC-SCH 1.0 group were less active than rats in the mPFC-SKF 0.5 (p < 0.0001) and 
mPFC-SKF 1.0 (p < 0.0001) groups. For P75 rats, there was an effect ofmPFC Drug 
(F(3,21) = 8.67, P = 0.001): Rats in the mPFC-Saline group were more active than rats in 
the mPFC-SCH 1.0 (p < 0.0001), mPFC-SKF 0.5 (p = 0.003), and mPFC-SKF 1.0 (p = 
0.007) groups. 
For the degree of effect produced by intra-mPFC drug treatment (mPFC-sal-
mPFC D1 agonist/antagonist), there was an effect ofmPFC Drug (F(2,.30) = 16.65, p < 
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0.0001), of Age (F(1,30) = 56.70, P < 0.0001), and an interaction that approached 
significance (F(2,30) = 2.78, P = 0.078). Activity was inhibited to a greater degree for 
rats in the mPFC-SCH 1.0 group compared to rats in the mPFC-SKF 0.5 and mPFC-SKF 
1.0 groups (both p < 0.0001). Activity was inhibited to a greater degree in adults than in 
adolescents for all treatment groups (all p < 0.01) (see Figure 4.6 d). 
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Figure 4.6. (a) Mean (±SEM) distance traveled in a 15 min baseline (pre-amphetamine) 
immediately after intra-mPFC injection of saline, Dl agonist SKF 81297, or Dl 
antagonist SCH 23390; (b) Mean (±SEM) difference in distance traveled in SKF 81297 
and SCH 23390 groups relative to saline in the 15 min baseline; @p30 < P75 (p = 
0.005); #p30 > P75 (p = 0.03). (c) Mean (±SEM) distance traveled after i.p. injection of 
0.5 mg/kg of amphetamine; (d) Mean (±SEM) difference in distance traveled in SKF 
81297 and SCH 23390 groups relative to saline groups after i.p. injection of 0.5 mg/kg 
amphetamine. 
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Experiment 4 Discussion 
In experiment 4, we tested two related hypotheses. First, we hypothesized that the 
0.5 mglkg dose of amphetamine would involve less activation of prelimbic D 1 dopamine 
receptors in early adolescent than adult rats based on previous evidence for reduced 
locomotor activity in adolescents compared to adults at this dose (Mathews & 
McCormick, 2009) and based on the lack of pre limbic Fos-ir induction at this dose in P30 
rats in experiment 2. Consistent with this hypothesis, injection of a DI dopamine receptor 
antagonist into the prelimbic mPFC resulted in less inhibition of locomotor activity in 
early adolescent compared to adult rats, indicating that adolescent rats may be less active 
than adults at the 0.5 mg/kg dose of amphetamine in part because this dose is less 
effective at activating prelimbic D 1 dopamine receptors in adolescence than in adulthood. 
In experiment 3, we found that the locomotor responding of adolescents to a 1.5 mglkg 
dose of amphetamine was disrupted more by an intra-mPFC injection of a DI receptor 
antagonist than was that of adult rats, which suggests that the locomotor activating effects 
of amphetamine are more dependent on these receptors in early adolescence than in 
adulthood. Thus, inadequate stimulation ofDI dopamine receptors at the low dose (0.5 
mglkg) of amphetamine in P30 rats may account for their reduced locomotor activity 
compared to adults. 
We further hypothesized that if reduced locomotor activity at the 0.5 mg/kg dose 
of amphetamine can in fact be attributed to inadequate activation of prelimbic D 1 
receptors, then injection of a D 1 receptor agonist into the mPFC of adolescent rats would 
increase locomotor activity in P30 rats, thereby reducing age differences in locomotor 
activity. This hypothesis was partially supported: An injection of the h~gher dose (1.0 
100 
/lglside) of a D 1 receptor agonist into the pre limbic mPFC increased the locomotor 
activating effects of 0.5 mglkg amphetamine in adolescent, but not in adult rats. 
However, rats treated with the D 1 agonist did not attain as high levels of activity as did 
adult rats, indicating that the enhancement of locomotor activity by activation of 
prelimbic D 1 receptors is not complete. In adults, the response to amphetamine requires 
additional effects on other neurotransmitter systems in the prelimbic mPFC that are also 
affected by amphetamine, including norepinephrine (Kuczenski & Segal, 1992) and 
glutamate (Del Arco, Martinez, & Mora, 1998). 
In contrast to the increase in adolescents, in adult rats, injection of a Dl receptor 
agonist into the prelimbic mPFC reduced the locomotor activating effects of 0.5 mglkg of 
amphetamine. The inhibition produced by a D 1 receptor agonist was comparable to that 
produced by a D 1 receptor antagonist. These data suggest that although D 1 receptor 
activation is necessary for the locomotor activating effects of amphetamine in adult rats, 
excessive stimulation of D 1 receptors also blocks the locomotor activating effects of 
amphetamine. Amphetamine increases dopamine release in the mPFC of adult rats 
(Maisonneuve, Keller, & Glick, 1990; Moghaddam & Bunney, 1989), which likely 
results in optimal D 1 receptor stimulation for enhancement of locomotor activity, 
whereas further addition of the D 1 agonist may result in over-stimulation of D 1 receptors. 
This interpretation is consistent with evidence that dopamine in the prefrontal cortex has 
an inverted U effect on locomotor activity in adult rats (Radcliffe & Erwin, 1996), and 
with previous reports of inhibitory effects of intra-mPFC D 1 receptor agonists on 
locomotor activating effects of systemic amphetamine in adult rats (Isacson, Kull, 
Wahlestedt, & Salmi, 2004). 
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General discussion 
Overall, the results of present experiments demonstrate that pre limbic D 1 
dopamine receptors have an integral role in regulating age dependent differences in the 
locomotor activating effects of systemic amphetamine. We found that early adolescent 
rats were the only group that exhibited increased prelimbic Fos-ir after 1.5 mglkg 
amphetamine. The results of D 1 agonist and antagonist administration into the prefrontal 
cortex suggest that D1 dopamine receptors are strongly recruited to regulate behaviour at 
the high dose (1.5 mglkg) of amphetamine during early adolescence, wherein these 
receptors contribute more to locomotor activating effects of amphetamine in early 
adolescent compared to late adolescent and adult rats. In contrast, a low dose (0.5 mglkg) 
of amphetamine is less effective at stimulating D 1 dopamine receptors in early adolescent 
than in adult rats, which suggests that dose-dependent age differences in locomotor 
activity involve differential activation of prelimbic D 1 dopamine receptors at different 
doses. 
Enhanced recruitment of D 1 dopamine receptors at high doses of amphetamine 
may have important implications for age differences in drug addiction. Intra-mPFC 
injections of a D 1 dopamine receptor agonist in adolescent rats increased preference for a 
low dose of cocaine, whereas a high dose of cocaine was sufficient on its own to produce 
strong place preference (Brenhouse, Sonntag et aI., 2008). Moreover, prelimbic D 1 
dopamine receptors have been implicated in resistance to extinction of conditioned place 
preference and with reinstatement of drug seeking in adolescent rats (Brenhouse et aI., 
2010), indicating that a greater role for D 1 dopamine receptors in regulation of 
102 
psychostimulant responses in adolescence may be associated with increased risk for drug 
dependence during this time. 
Age differences between P45 and adult rats were less evident than age differences 
between P30 and adult rats on all measures, indicating that the dopamine system begins 
to show signs of maturation by late compared to early adolescence, although much 
maturation continues past this age for many systems (e.g., sexual maturation, reviewed in 
McCormick & Mathews, 2007; evident in testosterone concentrations here). Greater and 
more lasting effects of drug treatments have been reported when drug treatment is given 
in early rather than later adolescence (Mathews, Kelley & McCormick, unpublished 
observations). In addition, studies with people have found that dependence problems are 
bigger in individuals who initiated drug use in early compared to late adolescence (Clark 
et aI., 1998; Estroff et aI., 1989; Merline et aI., 2004; Windle et aI., 2008). Thus, 
stabilization of D 1 receptor involvement in the regulation of psycho stimulant effects by 
late adolescence may be associated with reduced severity of dependence problems after 
early adolescence. 
Although the present results emphasize the importance of prelimbic D 1 dopamine 
receptors in regulating age differences in the locomotor activating effects of 
amphetamine, age differences in locomotor activity also involve developmental 
differences in the NAc. We have previously found that adolescents are more active after 
intra-accumbens injections of amphetamine than are adult rats (Mathews & McCormick, 
2009). In the present study, we found that pCREB and Fos-ir in the NAc are enhanced in 
adolescent compared to adult rats, which suggests that a higher dopaminergic tone in the 
NAc during adolescence may account for altered sensitivity ofthis region to 
amphetamine during adolescence. 
Conclusions 
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Consistent with the triadic theory of motivated behaviour, which proposes that 
prelimbic D I dopamine receptors drive behaviour more in adolescence than in adulthood 
(Ernst et aI., 2009), we have found that D 1 dopamine receptors in the mPFC positively 
regulate locomotor activating effects of amphetamine in early adolescence to a greater 
extent than in adulthood. Thus, mPFC D 1 receptors may be involved in enhanced risk 
for addiction particularly in early compared to late stage of adolescence. These fmdings 
may have implications for understanding addiction risk in people, as initiation of drug use 
in early adolescence is associated with more negative outcomes than initiation of drug 
use in late adolescence in people (Clark et aI., 1998; Estroff et aI., 1989; Merline et aI., 
2004; Windle et aI., 2008). 
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RATIONALE FOR STUDY 4 
The studies thus far have established that the ongoing development of the 
motivational neurocircuitry in adolescence is associated with age differences in the 
locomotor activating effects of acute amphetamine. Further, the fmding that a rapid 
increase in locomotor activity to a second injection of amphetamine was observed only in 
adolescent rats is consistent with the perspective that adolescents are uniquely vulnerable 
to effects of psycho stimulants. Nevertheless, it is not known from the studies thus far 
whether the change in sensitivity to amphetamine that was observed over the short time 
frame (24 h) in study 1 would result in more lasting alterations in amphetamine 
sensitivity in adolescent compared to adult rats, or if the enhanced sensitivity to 
amphetamine in adolescent rats would dissipate over time. 
Study 4 was designed to test the hypothesis that two days of pre-treatment with a 
low (0.5 mglkg) dose of amphetamine in early adolescence would produce-a larger and a 
longer lasting increase in amphetamine sensitivity than would the same pre-treatment 
procedure in adulthood. The inclusion of both an adolescent and an adult pre-treatment 
group provides a test of the hypothesis that adolescence is a sensitive period of 
development for the lasting effects of psychostimulants. 
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CHAPTER 5: LOW DOSES OF AMPHETAMINE LEAD TO IMMEDIATE AND 
LASTING LOCOMOTOR SENSITIZATION IN ADOLESCENT, NOT ADULT, 
MALE RATS 
Note: This section is based on the following article, with pennission: Mathews, I.Z., 
Kelly, H., & McConnick, C.M. (2010). Low doses of amphetamine lead to immediate 
and lasting locomotor sensitization-in adolescent, not adult, male rats. Pharmacology, 
Biochemistry and Behavior, in press. 
Abstract 
Although there is much evidence for age differences in behavioural responses to 
psycho stimulants in rats, the differential, lasting impact of drug exposures has rarely been 
investigated using direct comparisons of adolescent and adult rats. Male rats were pre-
treated with 0.5 mglkg amphetamine or saline on either postnatal days (P) 31 and P33 or 
P76 and P78, and locomotor activity was measured for 1 h. Adolescent, and not adult, 
rats showed a significant increase in distance traveled from the first to second pre-
treatment. There was no evidence of sensitization of locomotor activity in either 
adolescents or adults on Challenge 1 to the same dose of amphetamine when tested 12 
days later on P45 (late adolescence) or on P90. Rats that were pre-treated as adolescents 
exhibited locomotor sensitization to 1.5 mglkg amphetamine as adults (P60) on 
Challenge 2, 30 days after the initiation of pre-treatment, particularly in the group that 
had also received amphetamine on Challenge 1 at P45. Rats that were pre-treated as 
adults did not show sensitization on Challenge 2. The results suggest that the rapid 
adaptations to drug exposures in adolescence have greater consequences than identical 
treatment in adulthood, and highlight the unique vulnerability of adolescents to brief, low 
dose drug exposure. 
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Introduction 
Adolescents are less sensitive than are adults to psycho stimulants at first drug 
exposure (Weiss et aI., 1994), and they transition from drug use to dependence more 
rapidly than do adults (Wu & Schlenger, 2003). Moreover, risk for drug abuse in 
adulthood is greater in individuals who initiated first use in adolescence (Merline et at, 
2004), suggesting that exposure to psycho stimulants in adolescence may have unique and 
lasting effects on sensitivity to psycho stimulants in adulthood. Elevated risk for addiction 
in adolescence has been attributed in part to the heightened novelty seeking of 
adolescents (reviewed in Doremus-Fitzwater, Varlinskaya, & Spear, 2010). The neural 
pathways that mediate novelty-seeking, most notably the mesocorticolimbic dopamine 
system (reviewed in Bardo, Donohew, & Harrington, 1996), are also sites of action of 
psychostimulants, indicating that extensive developmental remodeling of this circuitry 
may underlie the differential vulnerability of adolescents and adults to drugs of abuse 
(e.g., Ernst et at, 2009). The changes in mesocorticolimbic circuitry in adolescence are 
similar in people and in rats and include changes in dopamine transporter density (people: 
Haycock et at, 2003; rats: Moll et at, 2000), dopamine receptor density (people: 
Montague, Lawler, Mailman, & Gilmore, 1999; Seeman et aI., 1987; Weickert et at, 
2007; rats: Andersen, 2003; Andersen et at, 1997; Andersen et aI. , 2000; Tarazi & 
Baldessarini, 2000; Tarazi et at, 1998), and tyrosine hydroxylase immunoreactivity (rats: 
Mathews et aI., 2009; people: Weickert et aI., 2007). 
In rodents, adolescence begins shortly after weaning and can be divided into 3 
stages (Tirelli et aI., 2003): Early adolescence spans the period after weaning and before 
puberty, lasting from approximately postnatal day 21 (P21) to P34. Mi.d-adolescence 
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encompasses the time shortly before and after puberty and lasts from P34 to P45, with 
puberty (as indicated by balanopreputial separation) occurring at approximately P42 in 
males (reviewed in McCormick & Mathews, 2007). Late adolescence begins on P45 and 
lasts until P60, when rats attain sexual maturity. As in people, adolescent rodents exhibit 
increased levels of novelty seeking (Stansfield et aI., 2004) and altered sensitivity to 
psychostimulants (Spear, 2000) compared to adults, indicating that studies with rodent 
models of adolescence can provide valuable insight into vulnerability to drug abuse in 
people. Consistent with age differences in psycho stimulant sensitivity in people, studies 
with rodents fmd that adolescents are less sensitive to the locomotor activating effects of 
acute psycho stimulant treatment than are adults (e.g., Adriani & Laviola, 2000; Bolanos 
et aI., 1998; Lanier & Isaacson, 1977; Mathews & McCormick, 2007; Mathews, 
Morrissey, & McCormick, 2010; Mathews et aI., 2009), and more sensitive to the 
locomotor sensitizing effects of repeated psycho stimulant treatment compared to adults 
(Adriani et aI., 1998; Laviola et aI., 1999; Mathews & McCormick, 2007; Schramm-
Sapyta et aI., 2004). Furthermore, behavioural sensitivity to amphetamine increases 
rapidly in adolescence, with locomotor activity increasing significantly in response to a 
second injection of amphetamine 24 h after the first injection in early adolescent (~P30), 
but not in adult rats (Mathews et aI., 2009). These latter studies involved testing confined 
to the adolescent period compared to the adult period, and did not address the extent to 
which any differences observed after adolescent treatment persist into adulthood. 
The few studies that have investigated possible lasting effects of psychostimulant 
treatment in adolescence have involved high doses and/or long periods of pre-treatment, 
and rarely involved a comparison group for which pre-treatment occ~ed in adulthood, 
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which is necessary to characterize the developmental-specificity of drug effects. For 
example, repeated pre-treatment with a high dose of amphetamine (2.0 - 10 mglkg) 
(Kolta et aI., 1990; McPherson & Lawrence, 2005) or cocaine (10 - 15 mglkg) (Marin et 
aI., 2008; Ujike et aI., 1995) in adolescence induced locomotor sensitization to a 
challenge dose of the drug in adulthood. Other studies have reported a sensitized response 
to amphetamine (Burton et aI., 2010; Valvassori et aI., 2007) and to cocaine (Achat-
Mendes et aI., 2003; Adriani et aI., 2006; Brandon et aI., 2001) in adulthood after chronic 
methylphenidate treatment in adolescence (but see Ferguson & Boctor, 2010), clearly 
indicating that repeated drug treatment in adolescence can induce locomotor sensitization 
in adulthood. Nevertheless, it is not known whether the effects described in the latter 
studies are unique to pre-treatment in adolescence, or if similar effects would be observed 
in rats pre-treated in adulthood. Studies using nicotine and methylphenidate that directly 
compared the effects of pre-treatment in adolescence or in adulthood suggest that lasting 
effects may depend on age. Whereas chronic methylphenidate treatment (2 mglkg twice a 
day for 15 days) in adulthood had no effect on locomotor activity, the same pre-treatment 
in early adolescence (P20 to P35) reduced sensitivity to the locomotor activating effects 
of cocaine in adulthood (Andersen, Arvanitogiannis-, · Pliakas, LeBlanc, & Carlezon, 
2001). In contrast, pre-treatment with nicotine (0.4 mglkg twice a day for 7 days) in 
adolescence, but not in adulthood, enhanced locomotor sensitization to amphetamine 30 
days later in adulthood (Collins, Montano, & Izenwasser, 2004). The latter studies 
suggest that lasting effects of chronic drug exposure may be greater in adolescents than in 
adults. 
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Here, we test the hypothesis that brief, low dose amphetamine exposures 
experienced in adolescence may be sufficient to increase the vulnerability to later drug 
exposures, and thus the present study involves a different approach than that of previous 
studies, which involved higher doses and/or more numerous pre-treatment injections. The 
treatment regimen we used [two injections of 0.5 mglkg amphetamine, which falls in the 
therapeutic dose range for ADHD (Heijtz, Kolb, & Forssberg, 2003) and in the low to 
moderate dose range for enhancement oflocomotor activity (Gulley et aI., 2007)], was 
based on our previous finding that early adolescent, but not adult rats,exhibited rapid 
behavioural sensitization to a low dose of amphetamine after a single pre-treatment 24 h 
earlier (Mathews, Waters & McCormick, 2009). Here, our goal was to determine 
whether such rapid sensitization in adolescent rats is temporary or would the effects of 
such a treatment regimen be observed after much longer intervals. The expression of 
behavioural sensitization after pre-treatment was examined at two different time points, 
once in later adolescence (12 days after pre-treatment) and again in adulthood (27 days 
after pre-treatment). Others have found that adolescent pre-treatment with amphetamine 
altered locomotor sensitization to amphetamine only in adulthood and not in adolescence 
(P37) (Santos, Marin, Cruz, DeLucia, & Planeta, 2009). Further, we have found rats in 
late adolescence (>P45, <P60) to differ from both rats in early adolescence and in 
adulthood on behavioural responses to drugs of abuse (Mathews et aI., 2009). Thus, the 
first challenge day for the adolescent pre-treatment group occurred in adolescence (P45), 
but in the post-pubertal phase. The second amphetamine challenge occurred 15 days· after 
the first challenge, when the rats were adults (P60); The second challenge involved a 
higher dose of amphetamine (1.5 mglkg) to improve the likelihood of ~etecting pre-
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treatment effects 27 days after pre-treatment, as the use of high challenge doses facilitates 
expression of sensitization when a low pre-treatment dose is used (Kuczenski & Segal, 
2001). Lastly, to test for the developmental specificity of the pre-treatment regimen, a 
group of rats underwent pre-treatment in adulthood, and was tested for behavioural 
sensitization after the same intervals (12 and 27 days) as those rats pre-treated in 
adolescence. Although others have found behavioural sensitization to amphetamine in the 
0.5 - 0.6 mg/kg dose range in adult rodents using numerous drug treatments (DA Hall, 
Stanis, Avila, & Gulley, 2008; Kelsey & Grabarek, 1999), we predicted that the use ofa 
brief pre-treatment period that is known to have different effects on sensitization of 
adolescent and adult rats in the short-term (Mathews et aI., 2009) would also reveal age 
differences in long-lasting sensitization. 
Method 
Animals 
Male Long Evans rats were purchased from Charles River Laboratories (St. 
Constant, QC, Canada) and arrived at the colony on either postnatal day 22 (P22; N = 34) 
or P60 (N = 34). Rats were housed in pairs and maintained on a 12h light-dark cycle with 
lights on at 0800h. Use of animals was approved by the Brock University Animal Care 
and Use Committee and followed Canadian Council on Animal Care and National 
Institutes of Health guidelines. 
Locomotor activity testing 
Locomotor testing was conducted in four white open top melamine arenas (58 cm 
X 58 cm X 58 cm) under indirect red light illumination to reduce anxiety associated with 
bright lighting. On P30 or P75, rats received an intra-peritoneal injecti~n of saline and 
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were immediately placed into the test arena for 1 h of habituation The pre-treatment 
phase began the next day and rats were randomly assigned to receive 0.5 mg/kg of 
amphetamine (n = 16 at each age) or saline (n = 18 at each age) immediately before 
placement into the locomotor test arenas for 1 h on each of two pre-treatment days, 48 h 
apart. Locomotor activity during the test sessions was recorded with a Sony digital video 
camera mounted from the ceiling and connected to the Smart tracking system (Smart; 
Panlab; Spain) that measured horizontal distance traveled. The first challenge day 
(Challenge 1) took place 12 days after pre-treatment on either P45 or P90 (see Table 5.1 
for the experimental design). 
Table 5.1. 
Experimental design. 
Adolescents 
Adults 
Saline 
pre-trea tmeat 
Amphetamine 
pre-treattllent 
Phases of · 
. . 
the 
experiment 
Age of testing for different pre-treatment groups 
P31 1/ P33 
P76 /1 P78 
Saline(S) 
n= 18 
(88) 
Amphetamine (A) 
n= 18 
(AA) 
Induction 
(O~5mg/kg) 
// 
Jf 
,/ 
P45 
P90 
S:1l=12 
(SSS) 
A: n=6 
(SSA) 
S:ll = 8 
(AAS) 
A: n=8 
(AAA) 
Challenge 1 
(O.5mglkg) 
II 
II 
P60 
PIOS 
S: ll = 6 
(SSSS) 
A:n=6 
(SSSA) 
A: 11 =6 
(SSM) 
A: n=6 
(AASA) 
A : 11 = 6 
(A,AAA) 
Challenge 2 
(1 .5 mg/kg) 
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For Challenge 1, rats in each drug pre-treatment group were assigned to receive 
either saline or 0.5 mg/kg of amphetamine. The second challenge (Challenge 2) took 
place another 15 days later when all rats were adult (either P60 or P105). Rats from each 
age at pre-treatment group were further divided into five groups: Rats that received saline 
during pre-treatment and saline on the first challenge day received either saline (SSSS 
group) or 1.5 mg/kg amphetamine (SSSA group) for Challenge 2, and rats that received 
saline during the pre-treatment phase and 0.5 mg/kg amphetamine on the first challenge 
day received 1.5 mg/kg amphetamine (SSAA) on Challenge 2. Rats that were treated 
with 0.5 mg/kg amphetamine during pre-treatment and saline on challenge 1 received 1.5 
mg/kg amphetamine (AASA) on Challenge 2. The fmal group of rats received 
amphetamine at all time points: 0.5 mg/kg during pre-treatment and on Challenge 1 and 
1.5 mg/kg on Challenge 2 (AAAA) (see Table 1 for the experimental design). Each rat 
was always tested in the same arena. All testing occurred between 0900h and 1700h and 
time of testing was counterbalanced across groups. 
Statistics 
Analyses consisted of mixed-factor ANOVA for pre-treatment days and between-
groups ANOVA for Challenge 1 and 2. Follow-up analyses for within-group comparisons 
were conducted using paired-samples t-test, and for between group comparisons, follow-
up analyses consisted of Fisher's least significant difference (LSD) test. Alpha level for 
statistical significance was set at p < 0.05, two-tailed, however, tests of a priori 
hypotheses with alpha levels ofp < 0.10 two-tailed are noted. 
Results 
Locomotor activity in the pre-treatment phase 
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A Pre-treatment Day (Pre-treatment 1, Pre-treatment 2) X Pre-treatment drug 
group (SS, AA) X Age (P30, P75) ANOV A on distance traveled found a significant Pre-
treatment Day X Pre-treatment drug group interaction (F(1,64) = 12.30, p = 0.001) and a 
near significant Pre-treatment Day X Age X Pre-treatment drug group interaction 
(F(I,64) = 3.75, p = 0.057). Follow up analyses were conducted by age to test the 
hypothesis that activity would increase from the first to the second pre-treatment in 
adolescent, but not in adult rats. For adolescent rats, a Pre-treatment Day X Pre-treatment 
Group ANOVA revealed a significant interaction (F(1,32) = 10.11, p < 0.01): For rats 
treated with saline, distance traveled decreased from the first to the second pre-treatment 
(p = 0.01) and for rats treated with amphetamine, distance traveled increased from first to 
second amphetamine pre-treatment (p = 0.04). In adulthood, there was no change in 
distance traveled for either saline or amphetamine treated rats (see Figure 5.1). 
For saline treated rats, adolescents were significantly less active than were adults 
during the first (p = 0.05) and second (p < 0.0001) day of pre-treatment, whereas the age 
difference between adolescent and adult rats after amphetamine treatment approached 
significance only during the first day of pre-treatment (p = 0.065; adolescent < adult) (see 
Figure 5.1). 
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Figure 5.1. Mean (±SEM) distance traveled during the two days of pre-treatment with 
saline or 0.5 mg/kg of amphetamine in adolescent or adult rats. Locomotor activity after 
amphetamine is shown in shaded bars. *p = 0.04 compared to activity on first pre-
treatment day in amphetamine-treated adolescents; **p = 0.01 compared to activity in 
on first pre-treatment day in saline-treated adolescents. 
Locomotor activity in Challenge 1 
An Age X Pre-treatment Drug X Challenge 1 Drug ANOV A on distance traveled 
on Challenge 1 revealed a main effect of Age (F(1,60) = 11.43, P = 0.001; adolescent < 
than adult) and a main effect of Challenge 1 Drug (F(1,60) = 122.83, P < 0.0001), with 
amphetamine treated rats more active than saline treated rats irrespective of pre-treatment 
drug. This pattern of results did not change when the analyses were conducted for each 
age group separately (see Figure 5.2). 
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LOCOMOTOR ACTIVITY ON CHALLENGE DAY 1 (P45 OR P90) 
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Figure 5.2. Mean (±SEM) distance traveled after treatment with saline or 0.5 mg/kg of 
amphetamine on Challenge 1, 12 days after pre-treatment. Locomotor activity after 
amphetamine is shown in shaded bars. *main effect of Challenge 1 drug treatment (p < 
0.0001). #main effect of age (p = 0.001). 
Locomotor activity in Challenge 2 
Because Challenge 2 did not involve a balanced design, the data for Challenge 2 
were analyzed with two different approaches. The frrst approach considered the five 
Challenge 2 groups (SSSS, SSSA, SSAA, ASAA, AAAA) as levels of one-factor. For 
rats pre-treated in adolescence (F( 4,29) = 15.44, p < 0.0001), all rats that received 
amphetamine for Challenge 2 were more active than rats that received saline (all p < 
0.0001). History of amphetamine treatment also had a significant effect on locomotor 
activity after an amphetamine challenge, such that rats that received amphetamine during 
pre-treatment and Challenge 1 (AAAA) were more active than both saline pre-treatment 
groups, whether or not they had amphetamine on Challenge 1 (SSSA, P = 0.04; SSAA, p 
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= 0.02). The higher activity of AAAA rats than AASA rats missed significance (p = 
0.07). For adult pre-treated rats (F(4,29) = 10.33, P < 0.0001), rats in all four groups that 
received amphetamine for Challenge 2 were more active than the group that received 
saline (all p < 0.0001), but no other group difference was significant (see Figure 5.3). 
The second approach was to have a balanced design for statistical analysis by 
removing the group treated with saline throughout the experiment (SSSS). A Pre-
treatment drug group X Challenge 1 drug group ANDV A of distance traveled in 
Challenge 2 for rats pre-treated in adolescence found that the higher locomotor activity in 
rats pre-treated with amphetamine compared to rats pre-treated with saline did not reach 
statistical significance (F(1,24) = 3.59, P = 0.07). No group difference approached 
significance for rats pre-treated as adults (see Figure 5.3). 
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LOCOMorOR.ACllVlTY .ONCHALlENS-e DAY 2 (PSOORP1OS) 
Figure 5.3. Mean (±SEM) distance traveled after treatment with saline or 1.5 mg/kg of 
amphetamine on Challenge 2. Groups denote assignment during pre-treatment to saline 
or amphetamine and during Challenge 1 to treatment with saline (Adolescents: S-45; 
Adults: S-90) or amphetamine (Adolescents: A-45; Adults: A-90). Amphetamine pre-
treatment groups are shown in shaded bars. *Denotes a significant difference compared 
to specified pre-treatment and Challenge 1 group (p < 0.05). @Denotes difference 
between rats that were pre-treated with amphetamine vs. saline in adolescence or in 
adulthood, irrespective of treatment on Challenge 1 (p = 0.07). 
Discussion 
The main finding of this study is that a brief treatment regimen with low doses of 
amphetamine in early adolescence leads to a lasting change in response to subsequent 
exposures, and highlight the heightened sensitivity of adolescents compared to adults to 
drug-induced behavioural plasticity. First, a low dose of amphetamine in adolescence, 
not in adulthood, increased the locomotor activating effects of a second injection of 
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amphetamine given 48 h later. Second, the rapid plasticity observed during the two days 
of pre-treatment in adolescence was associated with long-lasting locomotor sensitization 
to amphetamine, whereas pre-treatment was without effect on later responses to 
amphetamine in adults. Third, the enhanced sensitization observed in response to the 
second amphetamine challenge in adulthood can be attributed primarily to effects of 
amphetamine pre-treatment during early adolescence, though a combinatorial effect of 
amphetamine treatment during early and late adolescence seems to be the basis for the 
effect. That the same treatment regimen in adult rats had no lasting effect on locomotor 
activating effects of amphetamine is consistent with adolescence as a unique period of 
sensitivity to enduring effects of psychostimulants. Each of these findings and their 
implications are discussed in greater detail below. 
Locomotor activity during pre-treatment 
Consistent with previous reports of hyporesponsivity to an initial exposure to 
psycho stimulants in adolescence (Adriani & Laviola, 2000; Bolanos et aI., 1998; Lanier 
& Isaacson, 1977; Mathews & McCormick, 2007; Mathews et aI., 2010; Mathews et aI., 
2009), adolescent rats were less active than were adults to the first dose of amphetamine 
during the pre-treatment phase. In addition, only adQlescent rats exhibited a significant 
increase in the locomotor activating effects of amphetamine on the second pre-treatment 
day, confirming our previous report of rapid amphetamine-induced behavioural plasticity 
in adolescence (Mathews et aI., 2009). The increased activity in adolescents on the 
second test day eliminated the age differences that were observed for the first 
amphetamine treatment, indicating that the initial hyporesponsiveness cannot be 
attributed to age differences in amphetamine pharmacokinetics or to reduced locomotor 
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capacity in adolescents than in adults. Other studies have found that pharmacokinetic 
factors do not account for age differences in locomotor activity, in that brain levels of 
amphetamine, cocaine, or methamphetamine could not account for age differences in 
locomotor activity (Frantz et aI., 2006; Spear & Brake, 1983; Zombeck et aI., 2009). 
Furthermore, we have found age differences to acute administrations of a range of doses 
of amphetamine administered via cannulae directly into the nucleus accumbens (Mathews 
& McCormick, 2009). In addition, the increase in activity to a second treatment of 
amphetamine found in the present study cannot be attributed to a nonspecific increase in 
basal activity in adolescence, because adolescent saline-treated rats traveled less on the 
second than on the first day of pre-treatment. We have argued that the rapid change in the 
locomotor response to amphetamine in adolescence may reflect greater plasticity in the 
mesolimbic circuitry in adolescents than in adults (Mathews et aI., 2009), which is 
consistent with the report of a lower release of striatal dopamine in adolescent than in 
adult rats after acute treatment of amphetamine and a higher release in adolescent rats 
than in adult rats after repeated treatment of amphetamine (Laviola et aI., 2001). 
Locomotor activity on Challenge day 1 
Adolescent and adult pre-treated rats were tested for locomotor sensitization to 
0.5 mg/kg of amphetamine 12 days after pre-treatment (Challenge 1), when the 
adolescent group was post-pubertal (P45). Locomotor sensitization was not observed in 
either adolescent or adult rats at this time point, although activity appeared to be slightly 
higher in rats of both age groups that were pre-treated with amphetamine compared to the 
age-matched groups pre-treated with saline. In addition, we found that adolescent rats 
were less active than were adults after the amphetamine challenge on~45. We previously 
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found that, in contrast to P30 rats which attained adult-like levels of activity to a second 
treatment of amphetamine, P45 rats remained hyporesponsive (Mathews et aI., 2009), 
indicating that there are significant developmental shifts in drug responses within the 
time span conventionally considered as adolescence. Early and late adolescent rats differ 
on various behavioural and neural parameters, including conditioned place preference 
(Badanich et aI., 2006; Brenhouse, Sonntag et aI., 2008), cocaine-induced locomotor 
activity (Badanich et aI., 2008), cocaine-induced dopamine release in the nucleus 
accumbens (Badanich et aI., 2006), tyrosine hydroxylase immunoreactivity in the caudate 
nucleus (Mathews et aI., 2009) and dopamine receptor expression throughout the 
mesocorticolimbic dopamine system (Andersen et aI., 1997; Andersen et aI., 2000). Thus, 
lower locomotor activity in P45 rats compared to adult rats is likely a reflection of a 
developmental shift in neural regions that regulate the locomotor activating effects of 
psychostimulants. 
One possible explanation for the lack of sensitization at this age in adolescent pre-
treated rats is that the strong developmental difference in locomotor activity on P45 
masked any enhancement of activity that may have been produced by amphetamine pre-
treatment on P30. Others have shown that cross-sensitization to amphetamine after 7 days 
of nicotine pre-treatment in early adolescence was not found if the challenge test also 
occurred in adolescence, but it was found if the challenge test occurred in adulthood 
(Santos et aI., 2009). Similarly, effects of MDMA pre-treatment in adolescence on 
locomotor sensitization to cocaine increased with longer delays between pre-treatment 
and challenge day (Achat-Mendes et aI., 2003). Twice daily pre-treatment with 0.5 mglkg 
of amphetamine from P22 to P34 also failed to produce sensitization ~ rats when test for 
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sensitization occurred in late adolescence (~P48) (Heijtz et aI., 2003), but this study did 
not involve additional testing in adulthood. Thus, that changes induced by drug treatment 
in adolescence may be dormant until adulthood, is consistent with our results for 
Challenge 2 (discussed below). Another explanation for the lack of sensitization on 
Challenge 1 may be that the dose of amphetamine used on the fIrst challenge day was not 
sufficiently high to reveal sensitization, as the use of low doses of amphetamine for pre-
treatment and challenge sessions may compromise the ability to detect sensitization 
(Kuczenski & Segal, 2001). 
Locomotor activity on challenge day 2 
Adolescent and adult pre-treatment groups were challenged with 1.5 mg/kg of 
amphetamine on either P60 or P105, 27 days after pre-treatment. At this time point, 
locomotor sensitization was observed only in rats that were pre-treated with amphetamine 
in adolescence, indicating that enhanced plasticity observed after acute amphetamine 
treatment in adolescence produced effects that persisted into adulthood. Even though 
sensitization was greatest in rats that received amphetamine both during the pre-treatment 
period in early adolescence and on the fIrst challenge day on P45, a trend for sensitization 
was also found onP60 for those that received amphetamine on P30 and saline on P45, 
indicating that early adolescence (~P30) may represent a unique window of vulnerability 
to the effects of amphetamine. In contrast, rats given amphetamine for the fIrst time on 
P45 (Challenge 1) did not differ on P60 from rats given amphetamine for the fIrst time on 
P60, indicating that a single dose of amphetamine in late adolescence is not sufficient to 
induce locomotor sensitization 15 days later. 
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Most studies of the long-lasting effects of psycho stimulant treatment in 
adolescence have used methylphenidate (Achat-Mendes et aI., 2003; Brandon et aI., 
2001; Burton et aI., 2010), and those that have examined lasting effects of amphetamine 
(Kolta et aI., 1990; McPherson & Lawrence, 2005) and cocaine (Marin et aI., 2008; Ujike 
et aI., 1995) have used high doses (2 - 10 mglkg of amphetamine) and prolonged pre-
treatment periods. Here, we show that three days oflow-dose amphetamine in 
adolescence are sufficient for inducing sensitization in adulthood. This is an important 
point to consider because many studies have reported age differences in the locomotor 
activating effects of acute psycho stimulant treatment (Badanich et aI., 2008; Bolanos et 
aI., 1998; Lanier & Isaacson, 1977; Mathews & McCormick, 2007; Mathews et aI., 
2010; Mathews et aI., 2009), but the age-specific impact of acute psycho stimulant 
treatment on subsequent drug responses has not been thoroughly investigated. We found 
that acute amphetamine in adolescence contributed to rapid and enduring alterations in 
amphetamine sensitivity, as demonstrated by enhanced activity on the second pre-
treatment day and on the fmal challenge day. 
There is a lack of studies that directly compare the effects of amphetamine pre-
treatment in adolescence and in adulthood. A crucial advantage of including an adult pre-
treatment group is the ability to draw conclusions regarding effects that are unique to the 
developmental period at which the treatment occurred. Evidence for adolescence as a 
unique period of sensitivity during which exposure to various environmental stimuli can 
alter vulnerability to drugs of abuse is growing. Previous work from our lab has shown 
that exposure to a mild chronic social stressor throughout adolescence, but not in 
adulthood, increases locomotor sensitization to amphetamine in adulth~od (Mathews et 
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aI., 2008; McCormicket aI., 2005). Results of the present study extend these findings by 
demonstrating that three exposures to a relatively low dose of amphetamine administered 
during adolescence can also produce lasting effects on subsequent responses to 
amphetamine in adulthood. These data do not suggest that sensitization does not develop 
in adulthood. In fact, even a single pre-treatment with a high dose of 5.0 mglkg 
amphetamine has been shown to produce locomotor sensitization that increased with 
longer periods of withdrawal in adult rats (Vanderschuren & Kalivas, 2000). Instead, our 
data highlight the differential sensitivity of adolescents than adults for developing 
sensitization, even when exposure involves few treatments at low doses. One limitation 
of such developmental comparisons is that even though all rats have reached adulthood 
by the final test day, there is nonetheless a 45 day age discrepancy that confounds direct 
comparisons of locomotor sensitization because of differences in basal activity between 
young (P60) and older (PI05) adults. For this reason, it is critical that conclusions 
regarding age-specific pre-treatment effects on locomotor sensitization are limited to 
comparisons of age-matched controls, for which baseline activity is not an issue. 
Conclusion 
Comparable to age differences in drug effects in people (Weiss et aI., 1994), 
adolescent and adult rats differ in sensitivity to initial treatment with amphetamine. 
Importantly, acute amphetamine treatment produces adaptations that increase sensitivity 
to subsequent amphetamine treatment more readily in adolescent rats than in adults, 
indicating that very few low-dose amphetamine exposures in adolescence can have 
lasting consequences eventhough identical pre-treatment in adulthood has no detectable 
effect. Enhanced sensitization after adolescent pre-treatment in adulth<?od suggests that 
adolescence, particularly the early period, may represent a unique window of 
vulnerability to lasting effects of psychostimulants. 
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CHAPTER 6: GENERAL DISCUSSION 
The aim of this dissertation was to better understand how age differences in 
sensitivity to amphetamine map on to the development of the mesocorticolimbic 
dopamine system in adolescence. Locomotor activity was selected as the primary 
measure of sensitivity to amphetamine because the expression of amphetamine's 
locomotor activating effects requires coordinated activation of regions within the 
motivational neural circuit that are also involved in regulating the reinforcing effects of 
drugs (e.g., Pierce & Kalivas, 1997; Wise & Bozarth, 1987). Thus, acute amphetamine 
treatment can be used to elucidate age differences in the initial sensitivity of these 
underlying neural structures, whereas repeated amphetamine treatment can be used to 
draw inferences about developmental differences in neural plasticity. In addition, 
localized intracerebral injections of amphetamine and of dopamine receptor agonists and 
antagonists can provide important insights into the changing relationship between 
specific neural structures and behaviour as the organism develops. 
Model of age differences in sensitivity to amphetamine 
My investigation of the locomotor activating effects of amphetamine in relation to 
the development of the nucleus accumbens and the medial prefrontal cortex suggest the 
following model of the neural basis for age differences in amphetamine sensitivity (see 
Figure 6.1). The mesocorticolimbic dopamine system is in a hypoactive state during 
adolescence that can be overcome either with a higher dose (1.5 mg/kg), or with repeated 
injections of a lower dose (0.5 mg/kg), of amphetamine. The fact hypoactivity can be 
overridden suggests that age differences in amphetamine sensitivity may reflect a subtle 
increase in the response threshold of the nucleus accumbens and the m~dial prefrontal 
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cortex in adolescence. In addition, my finding of increased locomotor activating effects 
of intra-accumbens amphetamine in adolescent compared to adult rats suggests that 
hypoactivity to systemic amphetamine may involve a heightened influence of inhibitory 
brain regions outside of the nucleus accumbens in adolescence. 
The nucleus accumbens 
Locomotor hypo activity was observed to the 0.5 and not to the 1.5 mglkg dose of 
amphetamine (studies 1, 3, & 4), which suggests that the amount of stimulation required 
to activate the nucleus accumbens is elevated during adolescence. The elevated response 
threshold may be attributed to the reduced availability of dopamine pre-synaptically. Pre-
synaptically, reduced levels of basal tyrosine hydoxylase, the rate limiting enzyme in the 
synthesis of dopamine (study 1), and of dopamine (Badanich et aI., 2006) in adolescent 
rats may result in reduced dopamine release in response to lower doses of amphetamine. 
In fact, there is a report of lower dopamine release in response to acute amphetamine 
treatment in the caudate nucleus of adolescent rats (Laviola et aI., 2001). Post-
synaptically, higher expression of pCREB (Study 2), cAMP (Andersen, 2002), and 
dopamine D1 and D2 receptors (Andersen et aI., 2000; Tarazzi & Baldessarini, 2000), as 
well as a reduced ability of dopamine receptors to regulate cAMP (Andersen, 2002) may 
make it more difficult to distinguish weak signals from the high levels of "noise" in the 
nucleus accumbens during adolescence. 
Inhibitory regions 
Reduced sensitivity to a low dose of systemic amphetamine may also involve 
inhibitory effects of regions outside of the nucleusaccumbens, because adolescent rats 
were more active than were adults when amphetamine was administere.d directly into the 
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accumbens (study 2). A previous study has found that the hippocampus has a particularly 
strong inhibitory effect on the locomotor activating effects of amphetamine in 
adolescence, which was reversed by hippocampal lesions before the treatment with 
amphetamine (Lanier & Isaacson, 1977). Further, it has been hypothesized that the 
development of the amygdala may affect drug responses in adolescence (Ernst et a1., 
2009). In adults, the amygdala also has an inhibitory effect on amphetamine-induced 
locomotor activity rvv oods & Ettenberg, 2004) but the extent to which this inhibitory 
influence may change over adolescence has not been investigated. 
The medial prefrontal cortex 
My research indicates that activation of pre limbic D1 dopamine receptors may be 
a key factor in overcoming hypoactivity when the receptors are sufficiently stimulated, as 
with the 1.5 mg/kg dose of amphetamine. Consequently, hypoactivity at the 0.5 mg/kg 
dose may involve reduced stimulation of prelimbic D 1 dopamine receptors in 
adolescence, as evidenced by increased activity after treatment with a D 1 receptor agonist 
(Study 3). The higher threshold for activation ofDl dopamine receptors in the prelimbic 
mPFC may involve similar developmental factors as in the nucleus accumbens, including 
higher D 1 receptor density (Andersen et a1., 2000), reduced D1 receptor coupling to 
cAMP (Andersen, 2002), lower levels of tyrosine hydroxylase (Study 1) and reduced 
density of dopaminergic inputs from the ventral tegmental area (Kalsbeek et a1., 1988) in 
adolescent compared to adult rats. Moreover, the prelimbic mPFCis a major source of 
glutamatergic projections to the nucleus accumbens (Porrino & Lyons, 2000), which are 
regulated by prelimbic D 1 dopamine receptors (Brenhouse et aL, 2008). The density of 
these projections is lower in adolescent compared to adult rats (Brenh~use et aI., 2008), 
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indicating that higher levels of D 1 dopamine receptor activation may be required for the 
effective utilization of the available projections. 
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Figure 6.1. Graphical representation of findings from the thesis (bold) and from the 
literature that are relevant for explaining age differences in locomotor activating effects 
of amphetamine. Arrows within each box refer to the direction of the difference in 
adolescents compared to adults. 
Implications for drug abuse and addiction in adolescence 
Findings from the thesis research have implications for understanding the altered 
risk for drug abuse and addiction in adolescence. Prelimbic D 1 dopamine receptors are 
implicated in the development of addiction through potentiation of drug-seeking 
behaviour and reinstatement of drug-seeking after a period of abstinence (Everitt & Wolf, 
2002; Kalivas, Volkow, & Seamans, 2005; Sanchez et aI., 2003; Graham, Happenot, 
Hendryx, & Self, 2007; Brenhouse et aI., 2010). In adolescence, my results indicate that 
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low doses of amphetamine have insufficient action at pre limbic D 1 dopamine receptors to 
increase locomotor activity to levels comparable to adults. Thus, in adolescents, low 
doses have less of an effect on behaviour, which may increase the likelihood of repeated 
usage (e.g., Laviola et aI., 1999; Weiss et aI., 1994), thereby increasing the possibility of 
the drug-related changes in plasticity that underlie drug abuse. The results also indicated 
that although a higher dose resulted in the same level of activity in adolescents and 
adults, the locomotor response in adolescent rats reflected proportionally greater 
involvement of prelimbic D 1 receptors compared to adult rats. The latter results suggest 
that the same dose of amphetamine may lead to higher levels of drug-seeking in 
adolescent than in adult rats, which is consistent with the enhanced risk for addiction in 
adolescence in people (reviewed in Spear, 2000). 
The results from study 4 also highlight differential consequences of drug exposure 
in adolescents than in adults. In study 4, a short period of pre-treatment with a low dose 
of amphetamine resulted in longer lasting locomotor sensitization than did the same pre-
treatment protocol in adulthood, which is consistent with reports of faster transition from 
drug abuse to dependence during adolescence in people (Clark et aI., 1998). Overall, the 
findings of the present studies are consistent with the hypothesis that adolescence is a 
sensitive period of development for the effects of psychostimulants. 
Final comments 
Psycho stimulants like amphetamine act on the same neural systems that underlie 
motivation for natural rewards (Mogensen et aI., 1980). These systems direct attention to, 
and promote the approach toward, stimuli that are required for adaptation and survivaL 
Reorganization of receptors and synapses during sensitive periods of d~velopment 
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prepares the organism to meet the changing demands of each stage of development (e.g., 
Ernst et aI., 2009). For example, the motivational system in neonates is highly tuned 
toward the dam because of the high reliance on the dam for pup survival (Shair, 2007). 
As pups approach adolescence, motivational circuits are again reorganized to meet the 
changing demands of survival in unfamiliar environments away from the dam. The 
challenge of exploring greater territories and encountering new conspecifics is met by 
increased levels of risk taking, novelty seeking, and play behaviour during adolescence 
(Wahlstrom et aI., 2010; Spear, 2000). As rats approach adulthood, the demand for 
reproductive success leads to an increased interest in the opposite sex and a concomitant 
increase in inter-male aggression as they become competitors for territory and access to 
females (Thor & Carr, 1979). 
Developmental fme-tuning of the motivational system suggests that even when 
similar behavioural outcomes are observed, the underlying neural mechanisms may 
nonetheless differ with age. For example, the transient expression of parental behaviour 
in pre-pubertal adolescent rats (reviewed in Nephew, Lovelock, & Bridges, 2008) 
involves different neural and endocrine mechanisms than does the same behaviour in 
adults. The main implication of drugs acting on developmentally-distinct neural 
mechanisms is the potential to permanently alter the developmental trajectory of the 
underlying neural substrates, as exemplified by the age-specific development of 
locomotor sensitization in study 4 of the thesis. 
In conclusion, the same systems that promote resilience by supporting successful 
negotiation of developmental challenges can increase the engagement in risky behaviours 
that can lead to more severe maladaptive outcomes during adolescence. 
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AmphO.5 
Amph 1.5 
Cg1 
Cg2 
CREB 
l.p. 
pCREB 
mPFC 
NAc 
OVX 
P 
SCH 1.0 
SKF 0.5 
SKF 1.5 
TH 
TH-ir 
List of abbreviations 
0.5 mg/kg dose of systemically administered amphetamine 
1.5 mg/kg dose of systemically administered amphetamine 
Cingulate cortex 1; subregion of medial prefrontal cortex 
Cingluate cortex 2; subregion of medial prefrontal cortex 
Cyclic AMP response element binding protein 
Intraperitoneal route of systemic drug administration 
Phosphorylated cyclic AMP response element binding protein 
Medial prefrontal cortex 
Nucleus accumbens 
Ovariectomy 
Postnatal day of age 
1.0 Jlglside dose ofSCH 23390 (D1 receptor antagonist) 
0.5 Jlglside dose ofSKF 81298 CDI receptor agonist) 
1.0 Jlglside dose ofSKF 81298 CD1 receptor agonist) 
Tyrosine hydoxylase 
Tyrosine-hydroxylase immunoreactivity 
152 
Agonist 
Antagonist 
ligand 
CREB 
153 
Definitions of key terms 
A drug that mimics the effects of an endogenous ligand 
A drug that antagonizes or blocks the effects of an endogenous 
cAMP response element binding protein. A constitutively 
expressed transcription factor that is involved in regulation of gene 
expression 
c-fos The 1ene that codes for the fos protein 
fos The protein product of the c-fos gene. Expression is upregulated in 
response to synaptic activity, thus making this gene a useful 
marker of neural activity 
Intraperitoneal Injection of a drug into the body cavity 
Ligand A molecule that binds to a receptor ( e.g., dopamine) 
Phosphorylation A post-translational modification that alters activity of a protein 
pCREB Phosphorylated (the active form) of CREB 
Raclopride D2 dopamine receptor antagonist 
Second messenger Molecules that convey signals from membrane-bound receptors to 
targets 
SCH23390 
SKF 81297 
Tyrosine 
hydoxylase 
inside the cell 
D 1 dopamine receptor antagonist 
D 1 dopamine receptor agonist 
The rate limiting enzyme in the synthesis of dopamine and other 
catecholamines. Used as an indirect index of dopamine levels 
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